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ABSTRACT 
There are approximately 36.7 million people living with HIV while 1.8 million become newly 
infected every year. HIV belongs to the Retroviridae family and is an enveloped, positive sense 
(+) single stranded RNA virus. HIV has two subtypes, HIV-1 and HIV-2. HIV-1  is responsible 
for 95% of infections worldwide and is the focus of this thesis. There has not been any report on a 
conventional cure of this disease and the diagnosed HIV+ individuals need to receive lifelong 
treatment with antiretroviral drugs. Besides the antiretroviral drugs, there are host restriction 
factors that fight the infection in addition to the conventional immune barriers and responses.  
The APOBEC3 (A3) family of enzymes are part of an intrinsic immune system in humans and can 
act as host restriction factors to restrict the replication of HIV in CD4+ T cells by deaminating 
cytosine to uracil on the (-) DNA of HIV during reverse transcription. This promutagenic activity, 
if it occurs frequently enough, can cause viral hypermutation and inactivation. The A3 family 
contains seven members (A3A to A3H, excluding A3E) some of which developed gene variations 
that result in protein polymorphisms due to selective pressure over evolutionary time. These 
polymorphisms acquired enhanced antiretroviral activity to fight off HIV. To combat this, HIV 
has an accessory protein termed virion infectivity factor (Vif) that interacts with A3 enzymes and 
components of a Cullin5 E3 ligase complex. This complex causes ubiquitination and degradation 
of A3 enzymes in HIV infected host cells. 
HIV also has a high level of genetic variation that allows the virus to escape immunological and 
pharmacological barriers. Besides the lack of proofreading activity of reverse transcriptase, viral 
recombination and high rate of replication, the A3 enzymes have a potential role in increasing the 
genetic diversity of the HIV replicating pool if Vif mediated degradation is not complete. As a 
result, human A3 enzymes can contribute to this diversity directly by causing sublethal mutations 
and indirectly when the lethally mutated RNA genomes are “rescued” after virus recombination. 
While A3 enzymes may have this potential, and some research has found that A3 enzymes cause 
drug resistance mutations, other research groups have reported that in the presence of Vif the 
mutation rate of A3s is lower than the mutation rate of reverse transcriptase and their contribution 
to HIV evolution is not significant.  
To identify all the contributors to genetic variation of HIV and have a reliable answer for the 
current controversy in the field we aimed to determine the mutation rate of A3s in wild-type HIV-
iii 
 
1 infection and investigate if A3-induced mutations can yield drug resistant HIV-1 variants. 
Moreover, we aimed to study the restriction abilities of A3F allele variants carrying a single 
nucleotide polymorphism (SNP). We chose the SNP that causes the A3F 231I/V polymorphism 
because most people carry the heterozygous alleles. 
To test if A3 enzymes could contribute to HIV-1 evolution, we established a system to isolate 
HIV-1 drug resistant variants using peripheral blood mononuclear cells (PBMCs). We then used 
this method for a continuous spreading infection on infected U87 CD4+ CXCR4+ cells with a 
HIV-1 that was or was not exposed to A3G and A3F in a single replication cycle to discern the 
contributions of A3-mediated mutagenesis. The viruses were grown in the presence of increasing 
amounts of antiretroviral drugs. Viruses were collected and tested for viability using a reverse 
transcriptase activity assay. The data from four independent experiments with different drugs 
showed that A3G and A3F can induce drug resistance more times than when the virus was grown 
in their absence. However, drug resistant viruses exposed to A3G and A3F had less replication 
capacity than drug resistant variants that arose from HIV reverse transcriptase errors alone. 
Integrated proviral DNA and HIV genomic RNA (converted to cDNA) were sequenced to analyze 
A3-induced mutations. Importantly, for the first time we have quantified the amount of A3-induced 
mutations that occurs in the presence of Vif and shown that A3-induced mutations are 
approximately 4-fold above the background mutation level of HIV-1 reverse transcriptase alone. 
We also conducted similar experiments in CEM CD4+ T cells where endogenous A3 enzymes are 
expressed and obtained similar results. 
It is known that A3s have numerous polymorphisms which can affect antiretroviral activity of 
these enzymes. Namely, the CEM cells used in our experiments and numerous other labs have 
heterozygous alleles for A3F. As a result, we wanted to examine if the resulting A3F 
polymorphisms can be an additional factor that effects A3 activity in the presence or absence of 
Vif.  We found that the A3F 231V polymorphism, in comparison to the A3F 231I, resulted in 
higher expression and virus encapsidation in the presence and absence of Vif. Specifically, we 
observed approximately 4-fold more virus restriction and mutations in proviral DNA.  
Altogether, these data suggest that A3 enzymes can be a viable option as a therapy for HIV-1 if 
the interaction between Vif and A3s were disrupted. However, such a potential therapy would also 
depend on if the A3 genotype of the person contained highly active variants, such as A3F 231V. 
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1.0. INTRODUCTION 
1.1 HIV 
Human Immunodeficiency Virus (HIV) is grouped into the genus Lentivirus and the family 
of Retroviridae. It has emerged from Africa because of zoonotic transmissions of simian 
immunodeficiency virus (SIV) from primates to humans in the early 1900s due to injuries during 
meat butchering practices of hunted monkeys and chimpanzees1. Epidemic origins of the 
infection were tracked down to the 20th century in the Congo/Central Africa as a result of 
colonialism leading to cultural changes, such as, increased sex work and genital ulcer disease 
(GUD) outbreaks2. Independent transmission of SIV from chimpanzees and gorillas originated 
HIV-1 and its subgroups, M (main), O (outlier), N (non-M or non-O) and P (putative). Group M 
that is responsible for 95% of infections worldwide is divided into nine phylogenetic subtypes or 
clades (A, B, C, D, F, G, H, J, and K)3. Subtypes A, B, and C are the most prevalent forms of HIV-
1 worldwide where subtype C accounts for 50% of all HIV-1 infections4. Cocirculation of different 
subtypes in a population increases the chance of inter-subtype recombination. This recombinant 
virus is called a unique recombinant form (URF). When URFs are identified in at least three 
epidemiologically unlinked people, they are classified as circulating recombinant forms (CRFs). 
URFs and CRFs increase the chance of superinfection resulting in increased genetic variation of 
the replicating population of the virus3,4. The less pathogenic and transmissible type of HIV, HIV-
2, is limited to small regions in South Africa, Europe, India, and the United States5. HIV-2 contains 
8 groups (A–H), and is descended from sooty mangabeys6. Lower transmission rate of HIV-2 is 
correlated with lower viral load. Usually the HIV-2 viral load is approximately 37-fold lower than 
the viral load in HIV-1 infected individuals and appears to be responsible for the lower mother-to-
child transmission levels, rather than factors inherent to the virus7.  
1.2 AIDS  
HIV is a major global health problem, which has taken over 35 million lives so far. 
According to the WHO approximately 36.7 million people are living with HIV as of 2016. HIV is 
transmitted from exposure to body fluids of infected individuals (i.e. blood, breast milk, semen 
and vaginal secretions). The virus targets the immune system and causes depletion of CD4+ T cells 
and loss of their function which is the underlying cause of gradual immunodeficiency in infected 
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individuals (normal range for CD4+ T cell count is 500-1,500 cells/ml and <350 is immune 
deficient)8. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome 
(AIDS), which can take from 2 to 15 years to develop depending on the individual. This syndrome 
is characterized by the development of rare opportunistic infections (OIs) and/or cancers that 
people with healthy immune systems normally suppress9. Besides the pathological outcomes, 
HIV/AIDS has a great socioeconomic impact on the countries and individuals. Persons infected 
with the virus must not only cope with the disease but also, they may suffer from discrimination. 
Stigmatization against HIV/AIDS is associated with fear of death (instrumental stigma), symbolic 
association with homosexuality and injection drug use (symbolic stigma) and discrimination 
against people that are connected to HIV/AIDS (e.g., volunteers, children of parents living with 
HIV)10,11. 
1.3 Genomic Structure and Function 
The HIV virion contains two copies of single stranded positive-sense RNA molecules with 
a 5′ cap and 3′ poly(A) tail. The 9719 bp genome of the virus contains nine genes that encode 
fifteen viral proteins through three ORFs that are further categorized into three main groups: 
structural proteins, regulatory proteins and accessory proteins9,15. The 5′ long terminal repeat 
(LTR) region codes for the promotor and is followed by the gag (group-specific antigen) gene. 
The gag precursor is also known as assemblin because it plays a role in viral assembly. Gag is a 
55 kDa myristoylated protein, referred to as p55, that digests into matrix proteins (MA, p17), the 
capsid protein (CA, p24), the nucleocapsid (NC, p7) and a small Pro-rich protein (p6) by the viral 
protease12,13. Ribosome frameshifting near the 3' end of gag produces the gag-pol precursor. This 
precursor is subjected to cleavage by protease into reverse transcriptase/RNase H (RT, p66 and 
p51), protease (PR, p12), RNase H (p15) and integrase (IN, p32)9,14. In addition to gag and pol, 
HIV contains another structural protein, env. The env precursor (glycoprotein (gp)160) contains 
the gp120 (surface protein, SU) and gp41 (transmembrane protein, TM) glycoproteins that will 
reside on the external surface of the viral particle14 (Figure 1.1). HIV-1 and HIV-2 are similar in 
terms of structural and regulatory proteins. However, they have different accessory proteins6,9,15,16. 
Accessory proteins are used to antagonize host restriction factors. Host restriction factors are 
defined as host proteins that can specifically block a replication step of the virus17. Both HIV types 
contain the regulatory proteins, Tat and Rev.  
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1.3.1 Transactivator protein and RNA splicing-regulator 
Tat (transactivator protein) activates transcription of viral genes and regulates latency of 
the virus by binding to the host transactivation response (TAR) element and activating 
transcription initiation and elongation from the LTR promoter18. The RNA splicing-regulator, Rev, 
is a functionally conserved phosphoprotein. Rev cycles between the nucleus and cytoplasm but is 
primarily localized in the nucleus. This protein regulates the nuclear export of non-spliced and 
partially spliced viral mRNAs19,20. Besides the structural and regulatory genes, HIV has a set of 
accessory proteins that increase the pathogenesis of the virus and improve the viral fitness by 
counteracting the host antiviral responses. The accessory proteins Vif, Nef, Vpu, Vpr and Vpx lack 
any enzymatic activity. They interact with cellular factors to mediate degradation of host 
restriction factors, change their localization or redirect their normal function. It has been suggested 
that the function of accessory proteins has evolved as a result of the selective pressures of continual 
replication in primate hosts and interacting with host restriction factors21,22,9. 
1.3.2 Viral infectivity factor 
Vif (Viral infectivity factor) is an essential factor for the production of infectious virions 
in vivo and is found in all Lentiviruses, except equine infectious anemia virus. Studies have shown 
that Vif-deficient (ΔVif) viruses can replicate unaffected in many tissue culture systems. However, 
there is no report on clinical replication competent Δvif HIV isolates23. HIV-1 Vif is a cytoplasmic 
protein and targets host restriction factor APOBEC3 (A3) enzymes. A3s are deoxycytidine 
deaminases of single-stranded (ss) DNA that catalyze C to T mutations on the (-) DNA of the 
proviral genome during reverse transcription. Since my thesis investigates the interaction between 
HIV and A3 enzymes I will elaborate on HIV-1 Vif in more detail than other HIV proteins.  
The Vif protein mediates the polyubiquitination and subsequent degradation by the 26S 
proteasome of the five HIV restrictive A3 proteins (A3C S188I, A3D, A3G, A3H and A3F)23-26. 
Vif recruits an E3 ligase complex consisting of Cullin 5 (Cul5), Elongin B (EloB), Elongin C 
(EloC) and Rbx2 to mediate A3s degradation. Primate lentiviral Vif proteins also require Core 
Binding Factor b (CBF-β) for stability. Although Vif can only associate with the E3 ligase in the 
presence of CBF-β, the CBF-β is not a functional part of the E3 ligase complex. Importantly, CBF-
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β permits the biochemical purification of the tetrameric complex (CBF-β, Vif, EloC and EloB)27-
32. Vif by means of two domains, organizes the formation of Vif, CBF-β, EloC, EloB and Cul5 
pentameric complex (Figure 1.2). The larger domain (α/β domain) of Vif (red) binds to CBF-β 
(blue) (Figure 1.2). The α/β domain contains a five stranded antiparallel β sheet with three α-
helices that are tightly packed. The N-terminal region of Vif makes hydrophobic contact with 
residues on CBF-β. Vif is charged positively on its surface and this binding orientation keeps the 
positively charged surface exposed. The smaller domain contains two α-helices (α3 and α4) with 
a Zinc finger motif (H108-C114-C133-H139) between these two domains. The α3 binds to Cul5 
(orange) and shares some residues with Zinc finger motif in this binding (Figure 1.2). The α4 
harbors the BC-box motif that is required for interaction with EloC (Figure 1.2, yellow).  
Connection of EloB (magenta) to this hetero-oligomer is only through binding to EloC (Figure 
1.2)33. Vif also directly binds to the selected A3s and induces their ubiquitination which results in 
exclusion of the A3s from the cytoplasm. This decreased quantity effects the encapsidation 
efficiency of A3s in HIV-1 virions, which is an important step in restrictive activity of the A3s. 
1.3.3 Negative regulatory factor 
Nef (Negative regulatory factor) is expressed only in primate Lentiviruses and at the early 
stage of viral replication. Studies have shown that patients carrying Nef deficient viruses have 
delayed onset of AIDS as a result of long-lasting low level of viral replication34-36. Nef is a 
myristoylated protein that associates with plasma membrane and prenuclear membrane complexes. 
Nef is a multifunction protein that acquires its main activities as a result of connection to cellular 
vesicular trafficking machinery to disturb cell signaling37,38. Nef induces down-regulation of cell 
surface receptor CD4 from the plasma membrane by increasing its uptake into the endosome-
lysosome compartment. This protects the infected cells from cytotoxic super infection39. Nef hides 
the infected cells from the host immune cells by down regulating major histocompatibility complex 
class I (MHC-I) (reviewed in ref.40). Nef also causes T cell receptor (TCR) pathway dysfunction 
and promotes downregulation of CD28 receptor which is believed to be involved in the latency of 
the virus41. Nef directly binds to SERINC5 (Serine incorporator 5), a host restriction factor, and 
down regulates its cell surface expression via endosome-lysosome pathway. SERINC5 increases 
susceptibility of the Env to broadly neutralizing antibodies (BNAbs)42,43. 
CBFβ  
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1.3.4 Virus protein unique 
 Vpu (Virus protein unique) is only encoded in HIV-1. Vpu is a multifunction protein. It 
down regulates cell surface receptor CD4 in a multi-step process via ubiquitin-proteasome 
pathway44. Vpu facilitates release of viral particles through a Vpu ion channel activity45,46. 
Moreover, down regulation of CD4 increases the release of fully infectious virions. Vpu 
antagonizes the host restriction factor tetherin or BST-2 (Bone marrow stromal antigen 2)47. 
Upregulation of tetherin/BST-2 is triggered by interferon response caused by viral infection. 
Tetherin/BST-2 targets conserved regions of HIV-1 and inhibits the release of enveloped virus 
particles from infected cells47,48. Vpu directly interacts with tetherin and degrades it in a ubiquitin-
dependent endosomal pathway49. HIV-2 does not encode for Vpu but is able to antagonize tetherin 
using Env glycoproteins. SIV utilizes Nef protein to combat tetherin induced challenges50,51. 
1.3.5 Virus protein r 
 Vpr (virus protein r) is encoded in HIV-1 and HIV-2. Vpr is localized to the nucleus and is 
involved in transport and nuclear localization of the pre-integration complex (PIC). This assures 
replication of the virus in non-dividing cells like monocytes and macrophages. Vpu induces G2/M 
cell cycle arrest in proliferating cells52,53,54. G2/M cell cycle arrest and subsequent apoptosis 
enhances pathogenicity of the virus by providing additional time for virion packaging and protein 
synthesis55,56. Vpr blocks the cell cycle at G2 to mitosis transition and escapes from innate immune 
sensing by recruiting the host cellular factor SLX4 complex (SLXcom)55. SLX4com is an 
endonuclease involved in the repair of double stranded DNA breaks and stalled/collapsed 
replication forks by homologous recombination57,58. Vpr recruited SLXcom degrades excess HIV-
derived nucleic acids which can trigger the innate immune response upon accumulation (reviewed 
in ref59).  
1.3.6 Virus protein x 
 Vpx (Virus protein x) is unique to HIV-2 and SIV. Vpx is very similar to Vpr structurally 
and functionally and it is a product of gene duplication events in Vpr60. Vpx antagonizes the host 
restriction factor SAMHD161,62. SAMHD1 restrict replication of HIV during reverse transcription 
step by decreasing the levels of cellular dNTP pools63,64.  
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Figure 1.1 Schematic model of the HIV-1 full-length RNA genome. HIV-1 linear double-
stranded proviral DNA contains structural genes gag, pol, and env coding for matrix (MA), capsid 
(CA), Pro-rich protein, nucleocapsid core proteins (NC), protease (PR), reverse transcriptase (RT), 
RNase H, surface subunit glycoprotein (SU), and a smaller transmembrane protein (TM) and 
integrase (IN). HIV has six accessory gene products: Tat, Rev, Vif, Nef, Vpr, and either Vpu in 
HIV-1 or Vpx in HIV-2. The mRNA produced contains a CAP and poly A tail. Adapted from16.  
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Figure 1.2 Structure Vif-CBF-B-CUL5-ELOB-ELOC complex. U-shaped structure of the Vif-
organized Vif–CBF-β–CUL5–ELOB–ELOC complex. Overall structures of Vif–CBF-β–nCUL5–
ELOB–ELOC in two different orientations. Colour codes for the proteins are indicated. The dark 
blue spheres indicate Zn. Adapted from33. 
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1.4 HIV Replication Cycle 
The infection begins with the binding of gp120 to the CD4 receptor on T helper cells, 
macrophages, dendritic cells and astrocytes. This binding results in conformational changes and 
stimulates binding of gp120 to chemokine receptors (CCR5, CXCR4 or both). Binding of gp120 
to CD4 and to the co-receptor triggers an additional conformational change in gp41(TM). 
Attachment of viral particle to a host cell takes around 30 minutes to 2 hours. The gp41 protein 
subsequently forms a channel into the plasma membrane of the target cell resulting in fusion of 
cell membrane to viral envelope and viral entry (Figure 1.3, steps 1 and 2)6,15,65. 
Entry of the capsid into the cytoplasm activates the reverse transcription process. The host 
deoxynucleotide triphosphates (dNTPs) diffuse into capsid enabling DNA synthesis66,67 . During 
this process HIV (+) viral RNA is converted into a double stranded DNA (Figure 1.3, step 4). HIV 
packages two RNA genomes, resulting in a diploid genome, although only one proviral DNA is 
synthesized. The diploid genome benefits the virus by recombination through template switching 
at the DNA level and increasing the genetic diversity68 . The viral RNA is flanked at both ends by 
regulatory sequences (R-U5 at 5′ and R-U3 at 3′). During the reverse transcription the RNA 
dependent DNA polymerase part of reverse transcriptase uses a host tRNALys3 to synthetize a 
complementary strand of RNA (Figure 1.4). This newly synthesized (–) DNA will transfer from 
the 5′ end to the 3′ end through NC nucleic acid chaperone activity resulting in identical copies of 
LTRs containing the U3-R-U5 sequences at the ends of (–) DNA (Figure 1.4). The RNA strand of 
the resulting RNA-DNA hybrid is the substrate for RNase H. The RNase H activity of RT results 
in endonucleolytic cleavage of the genomic RNA, leaving the newly synthesized (–) DNA 
exposed. The HIV RT is a heterodimer containing the p66 portion with polymerase and RNase H 
functions and the p51 portion that is required for stability66,67 . However, there are two purine-rich 
patches in the RNA, called the polypurine tracts (PPT) that are resistant to the action of RNase H 
for longer68. As a result, the PPTs serve as primers for synthesis of the (+) DNA. Once the 18 
nucleotides of tRNA have been copied into the 3′ end of the (+) DNA, RNase H cleaves the tRNA 
and these exposed 18 nucleotides that are complementary to the Primer Binding Sequence (PBS) 
on the (–) DNA will anneal, resulting in the second strand transfer. Extension of the plus and minus 
strands by RT leads to the synthesis of the complete double-stranded linear viral DNA2,4,6,9,66,69. In 
order to integrate into the host genome HIV forms a pre-integration complex (PIC) which is 
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responsible for nuclear import. The PIC consists of the viral DNA, IN, RT, MA, and Vpr. MA and 
Vpr both contain nuclear localization signals (NLS) that are important for nuclear import 
(reviewed in ref70). After uncoating and removal of the capsid, the PIC, is transported to the host 
nucleus via nucleopores (Figure 1.3, step 5). It is believed that viral and cellular factors modulate 
the stability of the capsid. However, the exact location and time frame of uncoating process is yet 
to be determined (Figure 1.3, step 3)71.  
After integration (Figure 1.3, step 6), the viral DNA (now called proviral DNA) is 
replicated along with the host genome. Transcription (Figure 1.3, step 7) initiates from the U3 
promoter upstream LTR and requires the Tat protein for efficient elongation. Tat recruits cellular 
factors to TAR  element resulting in activating transcription initiation by DNA-dependent RNA 
polymerase (RNA Pol II) and elongation from the LTR promoter (reviewed in ref65). Transcription 
results in production of completely spliced small mRNAs which can independently get exported 
from the nucleus, or unspliced and singly spliced mRNAs that require Rev for nuclear export 
(Figure 1.3, step 8) (reviewed in ref 65). The completely spliced mRNAs serve as templates for 
Tat, Rev and Nef. Incompletely spliced mRNAs encode Env, Vpu, Vif and Vpr. Unspliced viral 
RNAs will incorporate into viral particles that will bud off the cell after assembly (Figure 1.3, 
step 9)72.  
HIV gag polyprotein (and its mature cleaved structural proteins, CA, MA and NC) is 
required for virus like particle (VLP) assembly and budding (Figure 1.3, steps 10 and 11). Gag 
associates with the plasma membrane and initiates all of the essential events for viral assembly 
like packaging the genomic RNA, creating spherical particles by protein-protein interaction and 
concentrating the Env protein. These assembling viral packages contain two copies of the viral 
RNA, cellular tRNALys,3, Env, Gag, PR, RT and IN73,74. HIV uses host trafficking machinery 
ESCRT (endosomal sorting complexes required for transport) for budding and virion release 
(Figure 1.3, steps 11 and 12) (reviewed in ref 73,75). Released virions undergo protease-mediated 
maturation during or after budding. Protease catalyzes lysis of the precursor peptides Gag and 
Gag–Pol to produce MA, CA and NC, and the enzymes PR, RT, and IN.  Mature virions are 
infectious and will target other CD4+ cells (Figure 1.3, step 13 )6,15,65,76.  
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Figure 1.3 Overview of HIV replication cycle. Step 1: Attachment of the envelope glycoprotein 
spikes (gp120 and gp41) to CD4 receptor and co-receptors this strep leads to step 2, fusion of virus 
and the cell membrane and entry of the virus particle into the cell. Step 3, uncoating. Step 4, 
reverse transcription and production of pre-integration complex (PIC). In the next step PIC gets 
imported into the nucleus (step 5), PIC-associated IN directs formation of the integrated provirus 
(step 6). After proviral transcription (step 7) viral mRNAs and unspliced RNAs are produced. The 
larger amount of which require energy-dependent export to leave the nucleus (step 8). Some 
mRNAs are used as a template for protein production (step 9) then full length RNAs and other 
expressed proteins are assembled into budding virions (step 10). The virion will bud off the cell 
through mediation of ESCRT (step 11) and release (step 12) from the cell. Then the virion will 
undergo PR-mediated maturation in step 13 to create an infectious viral particle. The site of action 
of cellular restriction factors are indicated with blue block signs. The site of action of antiretroviral 
drugs are in white box signs. Reprinted with permission from65. 
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Figure 1.4 HIV reverse transcription. Viral RNA is converted to a double-stranded DNA by 
reverse transcription. Reverse transcription is a nine-step process. Step 1, synthesis of the (-) DNA 
from the complimentary copy of positive strand of genomic RNA. Step 2, removal of the template 
RNA from RNA-DNA hybrid by the action of RNase H. Step 3, first strand transfer. In this step 
the (–) DNA is transferred from the 5’ end to the 3’ end of the RNA. Step 4, complete synthesis 
of the full length (–) DNA. Step 5, removal of the RNA. The PPT region is resistant to digestive 
action of RNase H and this residual RNA is later used in synthesis of (+) strand of DNA. Step 6, 
synthesis of (+) DNA is initiated by the PPT RNA primer and extends through the U3-R-U5 LTR. 
Step 7, removal of tRNA and PPT primer by RNase H. Step 8, second strand transfer. Step 9, 
extension of both DNA strands by reverse transcriptase. Reprinted with permission from77. 
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1.5 HIV Treatment 
There has not been any report on a conventional cure for HIV infection. Antiretroviral therapy 
(ART) on the other hand can suppress replication of the virus in an infected individual, increase 
peripheral blood CD4+ T cell counts and reverse immunodeficiency78. Currently the World Health 
Organization’s aim is to increase the coverage of ART throughout the involved populations using 
a 90-90-90 plan. The 90–90–90 plan, plans to have 90% of the people living with HIV knowing 
their HIV status, 90% of the people who know their HIV status receiving ART, and 90% of the 
people receiving ART having suppressed viral loads. This plan is aimed to be achieved by the end 
of 2020 and is aligned with the goal of ending the AIDS epidemic by 2030 (Figure 1.5)79. Currently 
global ART coverage for people living with HIV is 59% and 7 out of 10 pregnant women are 
treated with antiretroviral (ARV) drugs80. According to the latest consolidated guidelines released 
by WHO in 2016, all people living with HIV including children, adolescents and adults, pregnant 
and breastfeeding women, regardless of clinical stage or CD4+ T cell count (normal 500-1500, 
immunodeficient <350) should receive lifelong ART soon after diagnosis81,79. There are six classes 
of ARV drugs that target the virus in different steps of replication cycle (Figure 1.3)82:  
1) Nucleoside reverse transcriptase inhibitors (NRTIs) 
2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
3) Protease inhibitors (PIs) 
4) Integrase inhibitors (INSTIs) 
5) Fusion inhibitors (FIs) 
6) Chemokine receptor antagonists (CCR5 antagonists) 
The most effective method is the so-called highly active antiretroviral therapy (HAART), 
which is a combination of three or more ARV drugs from different categories. For an adult the 
most common ART is a fixed dose combination containing the NRTI tenofovir disoproxil fumarate 
(TDF); the NRTI lamivudine (3TC) or emtricitabine (FTC) and the NNRTI efavirenz (EFV). The 
patient who is receiving treatment goes under regular viral load monitoring twice in the first year 
and then every 12 months. Patients who are not stably on ART or are not virally suppressed should 
start the second and third line of ART. In adults, this regimen consists of two nucleoside reverse-
transcriptase inhibitors (NRTIs) plus a protease inhibitor (PI) (e.g. AZT and 3TC as the NRTIs 
and atazanavir (ATV/r) as the PI)79. Besides the use of ART in treatment of infected individuals, 
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ARV drugs are used before exposure to HIV by people who are not infected but they are at risk. 
This method of HIV prevention is called pre-exposure prophylaxis (PrEP). TDF alone or in 
combination with FTC is used commonly as PrEP79,83. At risk people are from key population that 
account for 50% of all new HIV infections worldwide. The key populations include (1) men who 
have sex with men, (2) people who inject drugs, (3) people in prisons and closed settings, (4) sex 
workers and (5) transgender people79,83.  
Post-exposure prophylaxis (PEP) is offered to individuals within 72 hours of an exposure that 
has the potential for HIV transmission. The preferred regimen for an adult is a 28 day prescription 
of combined TDF, 3TC (or FTC) and lopinavir (LPV/r) or ATV/r79. 
ART is a lifelong treatment that can increase life expectancy of a 20 year old HIV+ patient 
from 39 years to 70 years84. However, numerous side effects have been reported that differ 
depending on the class of the ARV drug, namely, lipodystrophy (body fat redistribution) by NRTIs 
due to their abilities to disrupt function of mitochondria and provoke apoptosis85-87. For PIs, 
metabolic abnormalities like hyperglycemia and insulin resistance have been reported85-87. 
NNRTIs are associated with rash and may cause Stevens-Johnson syndrome and toxic epidermal 
necrolysis 85-87. Over the last 15 years, as the scale of use of ART in HIV treatment and prevention 
has increased. Despite the significant benefits and positive contribution to public health of ART, 
there has been an increase in HIV drug resistance (HIVDR)80,88. HIVDR is caused by a mutation 
or mutations in the genome of HIV that changes the protein that the drug targets so that the ARV 
is no longer effective89. HIVDR in populations happens upon retention in treatment and care 
services that is caused by serious gaps in ART service delivery, drug stock-outs, negligence to 
monitor the viral load suppression in the first line of ART and changing the regimen to the second 
line of treatment, and inadequate support for population adherence to ART88. According to WHO’s 
action plan, NNRTI resistance among people on ART who are virally suppressed ranges from 4% 
to 28%, while it ranged from 47% to 90% among those with unsuppressed viral load on the first-
line NNRTI regimens and emphasizes the importance of viral load testing and switching to second-
line treatment upon confirmed virological failure89. HIVDR has substantial socioeconomical 
impact. Over the period of 2016–2020, the drug resistance is predicted to be responsible for 
135,000 deaths, 150,000 new HIV infections and cost the healthcare system US$ 650 million in 
sub-Saharan Africa89. Addressing all the contributors to HIVDR is of critical importance. A known 
14 
 
contributor to HIVDR is the HIV reverse transcriptase that has no proofreading activity and 
generates approximately 1 error per genome per replication cycle90. A potential contributor to 
HIVDR is the A3 deoxycytidine deaminases.  
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Figure 1.5 Percentage of people receiving ART over time. Adapted from91. 
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1.6 APOBEC 
The APOBEC family of enzymes are single-stranded cytidine deaminases that are named 
after the first identified member of the family, Apolipoprotein B mRNA editing complex 1, 
APOBEC1 (A1)92. Other members of this family are activation induced cytosine deaminase (AID), 
APOBEC2 (A2) , APOBEC3 (A3, there are seven members) and APOBEC4 (A4) (reviewed in 
ref77). These enzymes share similar functional and structural characteristics such as a single or 
double zinc-coordinating motif which catalyzes the deamination activity93. The common amino 
acid motif of the Zinc coordinating domain is H-X-E-X23-28-P-C-X2-4-C (where X is any amino 
acid). The histidine (H) and the two cysteines (C) coordinate a zinc atom and form the catalytic 
pocket. The cytidine will bind to this pocket. The glutamate (E) acts as a proton donor and activates 
the water molecule that is coordinated by the Zinc atom. The activated water deaminates the 
ammonium group on carbon 4 of the bound cytidine through a zinc-hydroxide-mediated 
nucleophilic attack93. The Zinc dependent deamination occurs on either mRNA or single-stranded 
(ss) DNA to form uracil94-96.  
Uracil in DNA is a lesion and the fate of this premutagenic lesion in DNA and subsequently 
the impact of APOBEC family is determined by the cell type in which the deamination occurs and 
the cellular DNA repair mechanisms (reviewed in ref 77) (Figure 1.6). AID is expressed in B cells, 
and deaminates the ssDNA generated from antibody genes that are undergoing transcription. The 
resulting uracils act as an initiator for error prone DNA repair to evolve and mature the antibody 
genes and enable immunoglobulin class switch recombination97. A1 is expressed in cells of the 
human small intestine and is involved in lipid transport. A1 deaminates cytidine at position 6666 
of apolipoprotein B mRNA and generates a stop codon (CAA to UAA). This translational stop 
codon truncates the 550-kD form of apo B, apo B100, to a smaller form, apo B48. Apo B48 is 
directly involved in lipid transport98,99. A2 and A4 do not have any catalytic activity. A2 is 
expressed in heart and skeletal muscles and plays an important role in muscle development and 
function93,100,101. A4 is expressed in testis tissue and the function of this protein is yet to be 
determined102. A3 enzymes are expressed in T cells, macrophages, and germ cells. Five out of 
seven members of the A3 family (i.e. A3C, A3D, A3F, A3G and A3H) can suppress replication of 
HIV-1 in CD4+ T cells in the absence of HIV Vif protein. These members can deaminate cytidines 
on the nascent cDNA (newly synthetized complementary DNA, (-) DNA) of the retrovirus when 
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it is single-stranded during reverse transcription. The use of uracils on the (-) DNA as a template 
for (+) DNA synthesis results in a hypermutated and nonfunctional virus103 (reviewed in ref77,92).  
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Figure 1.6 Overview of APOBEC family function. APOBEC family members are expressed in 
distinct cell types. A3A in monocytes and APOBEC1 in the small intestine edit RNA. AID 
deamination initiate antibody diversification pathways leading to somatic hypermutation and class 
switch recombination in B-cells. In CD4+ T cells, cytoplasmic A3s cause the deamination of 
retroviral ssDNA intermediates. A3s in monocytes and CD4+ T cells restrict foreign DNA 
reducing the DNA-induced inflammatory response. A3s may restrict retrotransposons in germ 
cells and somatic cells, through RNA binding or deamination of reverse transcripts. Unregulated 
A3 expression can lead to deaminations in genomic DNA leading to cell transformation or 
chromosomal instability both of which can lead to cancer. Reprinted with permission from77. 
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1.7 APOBEC3 
A3 enzymes are evolutionarily conserved cytidine deaminases and are expressed in 
lymphoid tissues of placental mammals. This family has seven members, A3A, A3B, A3C, A3D, 
A3F, A3G and A3H 104. A3G was the first member of the family that was discovered in 2002 by 
Sheehy et al, when they infected two different cell types CEM and CEM-SS with HIV-1 Δvif. They 
observed that the vif deleted virus could not replicate in CEM cells (non-permissive cell line) but 
the same virus could successfully replicate in CEM-SS cells (permissive cell line). The fact that 
HIV-1 Vif was crucial for successful replication of the virus in non-permissive cells lead to the 
discovery of the limiting agent in these cell lines, A3G (originally called CEM-15)23.  
Members of the A3 family share structural and functional characteristics with the rest of 
the APOBEC family. A3 proteins deaminate cytidine to form uridine in single-stranded DNA 
and/or RNA in a Zinc dependent manner 92,95,105. Gene duplication events on chromosome 22 have 
resulted in two groups of A3 enzymes with family members having either a single zinc (Zn)-
coordinating deaminase domain (A3A, A3C and A3H) or double Zn-coordinating domains (A3B, 
A3D, A3G and A3F) (Figure 1.7). The A3 Zn-coordinating deaminase domain (Z domain) is 
further classified into three distinct evolutionary clusters Z1, Z2 or Z3104,106,107. Z1 and Z2 domains 
have a Ser-Trp-Ser/Thr-Cys-X2–4-Cys motif, whereas the motif in Z3 domain is a Thr-Trp-Ser-
Cys-X2-Cys
108. The A3A, A3C and A3H enzymes with single Z domain have Z1, Z2 and Z3 type 
domain respectively. The A3 proteins with double Z domain have either one type of Z domain or 
a combination, for example A3B has (Z1-Z2), A3D (Z2-Z2), A3F (Z2-Z2) and A3G (Z1-Z2) and 
A3H is the only Z3 type domain107 104. However, only the C-terminal Z-domain is catalytically 
active in these enzymes109 107. 
A3s are considered part of the “intrinsic” immune system and act as host restriction factors 
against replication of retroviruses and retrotransposons. The mechanism of A3s function has been 
studied extensively in HIV-1 where, restriction of HIV primarily happens in the absence of Vif. 
A3C S188I, A3D, A3F, A3G and A3H haplotypes II, V and VII are present in the cytoplasm of 
infected cells and can restrict replication of HIV-1 in CD4+ T cells in Δvif condition (Figure 1.8A). 
The polymorphism in the population of A3s has different effects on the restrictive properties of 
the virus. A single nucleotide polymorphism (SNP) in A3C results in a 188I variant that is present 
at about a 10% frequency in diverse populations throughout Africa and has 10-fold more restrictive 
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activity than the common 188S A3C. This enhanced antiretroviral activity correlates with ability 
of this A3C 188S to dimerize. The A3C 188S is a stable monomer, whereas A3C 188I is in 
equilibrium between monomer and dimer110. A3H has seven major haplotypes (hap I to VII) with 
widely varying HIV restriction activity, due to different stabilities of the protein based on the 
haplotype.  Only Hap II, V and VII are stable in cells and have HIV restriction activity111,112. Hap 
II is the most prevalent of the “active” A3Hs and is present in 50% of Africans/African-
Americans111,113. Other haplotypes are partially active (Hap I) or not active (Hap III, IV and VI) 
due to degrees of stability/instability in cells. The instability is due to Δ15N and/or R105G 
mutation. It has been proposed that A3H evolved to become unstable due to a compromised cost 
to benefit ratio. Since these enzymes are promutagenic and A3H haplotype I can localize to the 
nucleus, it has been found to induce mutagenesis of DNA in lung and breast cancer114 . It has been 
hypothesized that this “off-target” activity in the genome was beneficial for restriction of an 
ancient pathogen, but since this pathogen has been fully suppressed the maintenance of A3H comes 
at a cost to the host111,115.  
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Figure 1.7 Z-type domains of human A3 enzymes. APOBEC3 enzymes contain either a single or 
double Zn coordinating domain. There are 3 types Z1, Z2, and Z3. A3H is the only Z3 family member. 
A3B and A3G contain each a single copy of the Z1-type domain. Single domain A3s contain all 
biochemical characteristics on that single domain whereas double domain enzymes delegate functions 
to either domain. Reprinted with permission from92. 
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1.7.1. Mechanisms of HIV-1 restriction by APOBEC3 enzymes 
When a CD4+ T cell is targeted by HIV-1 and the virus fuses with the cell, the capsid of 
the virus enters into the cytoplasm of the infected cell. The uncoating event, which is the process 
of removal of the capsid, exposing the viral nucleic acid does not happen immediately. However, 
the host dNTPs present in the cytoplasm diffuse into the capsid and the reverse transcription 
process begins116. A3s with antiretroviral activity (A3F, A3G, A3H, A3D, and A3C S188I) are 
present in the cytoplasm of the infected cell but they cannot access the ssDNA of viral genome 
during reverse transcription due to the timing of the uncoating process and impermeability of the 
capsid to cellular proteins. For A3s to be restrictive and access ssDNA of the virus during reverse 
transcription they must become encapsidated into assembling virions in the HIV producer cell by 
binding to the cellular and viral RNAs. A3s are able to do this by binding to RNAs with the same 
sequence preferences as the NC domain of Gag that packages the HIV-1 RNA117. The 
encapsidation of A3s is inhibited by the viral protein, Vif. The Vif protein mediates 
polyubiquitination of A3 proteins by directly binding to the A3 enzyme and recruiting an E3 ligase 
complex resulting in degradation of the A3s by 26S proteasome (Figure 1.8A)118.  Due to natural 
variation in the HIV population there are alleles of Vif with partial activity against A3 enzymes 
that fail to neutralize one or several A3s119,120. Moreover, even a fully active Vif is not able to 
suppress A3s completely as one to two A3s with potential deamination activity can still get 
encapsidated in the presence of Vif25,121-124. 
The encapsidated A3s travel with the virus to the next target cell and mediate inhibition of HIV-1 
replication by means of two mechanisms deamination-dependent restriction of HIV-1 and 
deamination-independent restriction of HIV-1. 
1.7.2. Deamination-dependent restriction of HIV-1 by APOBEC3s 
After entry of the virus to the next target cell, A3F, A3G, A3H, A3D and A3C S188I 
interfere with HIV replication by catalyzing the formation of numerous uracils from deamination 
of cytosine in the (-) DNA at “hot spots”. These hot spots are preferred motifs for A3 deaminase 
activity and are 5'CCC for A3G or 5'CTC for A3H, 5'TTC for A3F and 5'TC for A3D and A3C 
S188I. The uracils are used as a template during (+) DNA synthesis, which results in C/G→T/A 
transition mutations that alters the transcription, coding, fitness, replicative capacity and viability 
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of the provirus after integration into the host genome (reviewed in ref77). Alternatively, the uracils 
may prevent proviral integration. This is because host uracil DNA glycosylase (UNG), a base 
excision repair (BER) enzyme in the nucleus, can excise the uracils leading to further processing 
by apurinic-apyrimidinic endonuclease (APE) that cleaves the DNA backbone at abasic sites. If 
these sites are numerous, this can lead to degradation of the proviral DNA before integration 
(Figure 1.8B and reviewed in ref77).  
Although the selected A3s have an overall similar deamination-dependent mechanism to 
restrict HIV-1, there are some differences in terms of scanning mode, oligomerization and 
processivity of these enzymes. A3 enzymes recognize cytidines in specific motifs, but they must 
first find these motifs in a length of otherwise nonspecific ssDNA125-127. Scanning is the process 
of searching the ssDNA for these motifs in an energy independent manner using facilitated 
diffusion128,129. In facilitated diffusion, enzymes use the electrostatic interaction with DNA to 
facilitate their Brownian motion (Figure 1.9A)128,129. There are different modes of scanning, i.e., 
sliding, jumping and intersegmental transfer128-130. Sliding happens when the enzyme diffuses 
along the phosphate backbone, searching < 20 nt of DNA (Figure 1.9B). In jumping, the enzyme 
undergoes micro dissociations and reassociations with the same DNA strand without diffusion into 
the bulk solution (Figure 1.9C). In intersegmental transfer, an enzyme with two DNA-binding sites 
binds a second site before releasing the first site in a two-step movement (Figure 1.9D). Jumping 
and intersegmental transfer are efficient for covering > 20 nt of the target DNA but they lack local 
scanning of small segments128-130 (reviewed in ref77,92). A combination of two or three scanning 
modes is crucial for a inducing enough deaminations in the limited time that the (-) DNA is single-
stranded.  
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Figure 1.8 APOBEC3-retroviral interaction lifecycle. (A) APOBEC3 mediated inhibition of 
HIV-1. APOBEC3 proteins are part of the host restriction enzymes against retroelements. These 
proteins are in the cytoplasm of the infected cells and to be restrictive they should coencapsidate 
into the assembling viral particles, travel with the particle to the next target cell, then mutate the 
viral cDNA during reverse transcription. These lesions cause G-to-A hypermutations and change 
the replicative capacity of the virus. However, HIV Vif mediated ubiquitination and subsequent 
degradation of A3s by 26S proteasome. Reprinted with permission from131. (B) Schematic of the 
consequences of uracil after cytosine deamination in genomic DNA. In the absence of repair, 
replication of the U results in a T/A base pair instead of a C/G base pair. Uracils created by cytosine 
deaminations are removed by uracil DNA glycosylase (UNG) to create an abasic site which can 
be processed by AP endonuclease (APE). APE cleaves the DNA backbone at the abasic site to 
enable repair by base excision repair (BER) polymerases or the mismatch repair (MMR) pathway. 
DNA breaks can occur if the abasic sites are located close together. It is possible for this lesion 
can be bypassed through error free mechanisms or gap-filling DNA synthesis. Error prone repair 
can occur by translation synthesis polymerases synthesizing DNA within the gap, depending on 
cellular conditions. Adapted from77.  
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Figure 1.9 APOBEC3 scanning mechanisms. (A) Drawing showing the negative charge region 
of DNA where A3 enzymes inhabit when they interact with DNA. (B) Sliding, short local scanning 
(<20 nucleotides). (C) Jumping, longer distance scans where the A3 continues to remain the 
negative charge region but can scan over double stranded regions of DNA (>20 nucleotides). (D) 
Intersegmental transfer, this mechanism of scanning involves a doubly bound state. Reprinted with 
permission from77 . 
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1.7.2.1 Processivity of APOBEC3 enzymes involved in restriction of HIV 
Processivity is the mechanism of deaminating multiple cytosines in a single enzyme-
substrate encounter. The level of processivity differs as a result of A3s’ scanning mechanism132. 
A3G enzyme is able to induce deamination using both sliding and intersegmental transfer. This 
ability benefits the enzyme to have an efficient function133,134. A3F is another contributor to 
restriction of HIV. However, A3F enzyme does so less efficiently than A3G. This can be attributed 
to lack of sliding ability of A3F. A3F can only scan the target DNA using jumping motions133. 
A3H is the only member of the family with different haplotypes (I-VII), among these only 
haplotype II, V, and VII can restrict HIV111. A3H Hap II and Hap V can utilize both sliding and 
jumping/intersegmental transfer to facilitate an efficient scanning135. The enhanced antiretroviral 
activity of the A3C S188I polymorphism is due to a change in the dimerization state of the enzyme 
from monomer to monomer/dimer, with the ability to dimerize being correlated with improved 
processivity. The dimer enables sliding, jumping, and intersegmental transfer movements of A3C 
S188I110. A3D is the least studied member with antiretroviral activity. This enzyme is less 
restrictive in comparison to A3F, A3G and A3H and the restrictive capacity of the enzyme is 
comparable to the less restrictive variant of A3C. However, A3D has not been purified and 
characterized biochemically to determine if this is due to differences in the processivity. It has 
been found that A3D in primates is more active and the activity of A3D was lost during evolution 
from chimpanzees to humans136,137. 
1.7.3 Deamination-independent restriction of HIV-1 by APOBEC3  
Besides the deamination dependent restriction of HIV-1 by A3s, which is the main 
mechanism to inhibit replication of the virus, some A3 enzymes have deamination-independent 
restriction ability. In deamination-independent restriction, A3s suppress some processes such as 
tRNA primer binding, initiation and elongation of reverse transcription, plus strand DNA 
synthesis, or integration138-143. One explanation for the mechanism underlying inhibition of these 
processes is that A3F and A3G bind to the primer template and act as a “road-block” to RT 
polymerization or interact directly with RT, which slows down the extension of the 
template139,144,145. Deamination independent properties of A3F are stronger than A3G and this 
mode of restriction accounts for 30% of the total viral restriction by A3F146. Whereas, this portion 
is less than 1% for A3G146. The enhanced deamination independent restriction by A3F could be 
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due to higher affinity of the enzyme in binding to DNA and polymerization of the enzyme on the 
target DNA that leads to a physical obstacle for the RT139,144. 
1.8 HIV overcomes antiretroviral drugs and host restriction factors 
Although HIV only codes for 15 proteins it has a high level of genetic variation that allows 
the virus to escape immunological and pharmacological barriers. Not only has this genetic 
variation made it difficult to design a successful vaccine but also drug-resistant HIV strains can be 
transmitted from one patient to another and leave the infected individual nonresponsive to the 
medication before it is ever received. To overcome this, it is crucial to understand all contributors 
to HIV genetic diversity.  
A combination of factors contributes to this genetic variation: 
1) High replication and mutation rate: As the rest of Retroviridae family, HIV-1 has a high 
mutation rate that has been evaluated between 10-4-10-5 mutations/bp/replication cycle90 . 
This high rate of mutation is a result of lack of proof reading ability of reverse transcriptase. 
This high mutation rate is coupled with high replication rate and production of 1011 
virions/day/patient and 107-108 infected CD4+ T cells147,148. 
2) Recombination: HIV is a diploid virus which means every particle carries two RNA strands 
that come from the same host cell. If a cell gets infected twice (termed superinfection), the 
host genome will simultaneously harbor two different proviruses. During virion 
encapsidation one RNA transcript from each provirus can get packaged into a 
“heterozygous” virion. Upon infection of a new cell with this virion, the reverse 
transcriptase due to its low processivity can transfer back and forth between the two RNA 
templates (template switching), which can result in synthesis of a recombinant virus 
(Figure 1.10A)149. 
3) APOBEC3 selective pressure: Due to natural variation in Vif there are partially active Vif 
proteins present in the virus population in an HIV+ person. These partially active Vif alleles 
are less effective in mediating degradation of A3s150. Moreover, fully active Vif proteins 
are not able to fully suppress A3s completely and 1-2 A3s with potential deamination 
activity can still get encapsidated151. The G-to-A mutations induced by A3 proteins have 
been proposed to modulate HIV-1 fitness and lead into increased genetic variation in the 
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HIV population by two mechanisms (Figure 1.10B). First, through lethal mutagenesis, 
dead proviruses are generated that cannot increase genetic variation of the replicating viral 
population. However, parts of the proviral genome harboring such mutations can get 
rescued when a replication-competent virus infects the same cell and HIV copackages one 
faulty and one competent viral RNA genome152. This allows for recombination during 
reverse transcription and leads to presence of sublethally mutated genomes in the 
replicating viral population. Second, sublethally mutated viruses can be generated directly 
by low levels of A3-mediated mutagenesis and increase genetic variation of the replicating 
viral population152. 
The fate of the mutations that are caused by A3s are determined by the location and 
the frequency of these mutations. It has been shown that if the mutation occurs in TGG 
codon of tryptophan by A3G or in ATGGA context by A3F, the concomitant G to A 
mutation changes the TGG codon to a TAG stop codon. Insertion of premature stop codons 
is considered a lethal mutation and can lead into production of nonviable virions, if not 
rescued during recombination (Figure 1.11)77. 
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Figure 1.10 APOBEC mutagenesis of HIV. (A) RNA Recombination in HIV. The coinfection 
with two replication competent virions can cause generation of “heterozygous” virus particles 
containing RNAs from different parent viruses, if this viral particle infects another cell after 
template-switch and recombination events, infectious recombinant proviruses are produced and 
released into the population. Figure adapted from149. (B) Flow chart of potential contribution of 
hypermutation and recombination to HIV genetic diversity. Figure adapted from reference152. 
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Figure 1.11 Fate of tryptophan codons. The process of insertion of premature stop codons by 
A3F and AF involving tryptophan in (−) DNA (5′CCA). Reprinted with permission from77. 
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1.9 Rationale and Hypothesis 
 Five of the seven A3 enzymes in humans can restrict the replication of HIV by becoming 
encapsidated into budding virions and deaminating cytosine to uracil on the (-) ssDNA during 
reverse transcription. When this (-) DNA is used as a template to synthesize the (+) DNA, the 
uracil lesions result in transition mutations. The effect of the mutations on the fate of the virion is 
dependent on the number and position of these mutations. HIV has a genome of ~104 bp and has 
a mutation rate of 1 in 104 nucleotides per genome during one replication cycle, which considering 
the daily turnover of 1011 viral particles, results in a viral quasi-species population during chronic 
infection in the host147,153,154. Moreover, the footprint of mutation by A3s in specific sequence 
contexts in the HIV genome has been found by sequencing integrated proviral genomes from HIV+ 
people. Analysis of patient proviral sequences has shown ~25% G to A hypermutations in A3 
preferred dinucleotide motifs (5′GG→AG for A3G and 5′GA→AA for A3F, A3D and A3H)155,156. 
These data support the fact that even in the presence of Vif, the HIV is unable to completely induce 
degradation of A3 enzymes such that A3s may contribute to genetic variation of HIV. However, 
RT errors also have a G→A substitution bias, but in an unidentified surrounding sequence context. 
Importantly, in the absence of selective pressure, the population of drug resistant mutants is as low 
as 0.5-1% but they can rapidly grow under drug selection and maintain HIV production157,158. 
Given that, an in vitro study by Mulder et al. showed that mutagenesis caused by A3s that were 
not degraded completely by partially defective Vif proteins exceeded the rate of errors generated 
by RT150. They also show that these mutations induced appearance of 3TC resistant variants under 
drug selection pressure150. Conversely, some groups have shown that mutation caused by A3s may 
lead to a decrease in genetic diversity by reducing the rate of recombination due to decreased 
homology between the copackaged RNAs152. In 2013 Fourati et al., in a study on 30 HIV infected 
individuals’ peripheral blood mononuclear cells (PBMCs) body tissues, and fluids found the 
presence of drug resistant mutations in PBMCs with no inactivating mutation in RT or PR 
sequences and concluded that a combination of cytidine deamination and genomic RNA 
recombination results in emergence of drug resistant variants159. Interestingly, this group showed 
that the amount of hypermutation in the samples from the tissues exceeded those in PBMC samples 
and suggested that although these mutations can favor escape of HIV from pharmacological 
barriers, accumulation of defective viruses may be more dominant in tissues in comparison to 
PBMCs under pressure of ART159. 
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Considering all these findings, we hypothesize that G→A mutations caused by A3 enzymes leads 
to increased genetic diversity in the replicating population of the virus and that such mutations can 
lead to drug resistance and escape of the virus from ARV drugs. We further hypothesize that the 
ability of each member of the A3 family to induce such mutations is variable depending on the 
polymorphisms.  
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1.10 Specific Aims 
We tested the hypothesis with the following specific aims.  
 
Aim 1: Determine the HIV-1 mutation level caused by A3s in the presence of Vif. 
Aim 2: Investigate if A3-induced mutations can contribute to the evolution of the virus and 
yield in drug resistant variants. 
Aim 3: Identify the HIV restriction activity of the A3F 231I and A3F 231V 
polymorphisms, in cooperation with A3G and alone. We aimed to study the A3F 231I/V 
polymorphisms because most people carry a heterozygous allele of 231I/231V136,160.  
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2.1 Abstract 
APOBEC3 deoxycytidine deaminases are host restriction factors of HIV-1. The APOBEC3 
enzymes that can become encapsidated into HIV-1 virions are able to induce mutagenesis of 
proviral DNA through the deamination of cytosine in HIV-1 (-) DNA, which forms promutagenic 
uracil and results in G→A mutations. HIV-1 overcomes this host restriction through the viral 
protein Vif that binds to and induces APOBEC3 polyubiquitination and proteasomal degradation 
by acting as the substrate receptor for a host E3 ubiquitin ligase. There is a balance between Vif-
mediated degradation of APOBEC3 enzymes and APOBEC3 deaminase activity that determines 
the number of mutations incurred by a provirus and if the mutations result in viral inactivation. 
Within this dynamic relationship, the APOBEC3 enzymes have been found to be beneficial, 
neutral, or detrimental to several aspects of HIV-1 host adaptation such as CTL escape, co-receptor 
usage and antiviral drug resistance. Here, we assessed the ability of coexpressed APOBEC3F and 
APOBEC3G to induce HIV-1 drug resistance to several antiviral drugs. We found that the 
APOBEC3F and APOBEC3G, that has been previously shown to form a hetero-oligomer in cells, 
enabled partial resistance of APOBEC3F to Vif-mediated degradation with a corresponding 
increase in APOBEC3F encapsidation and deaminations in the presence of Vif. The resulting 
deaminations of APOBEC3G and APOBEC3F were above the RT-induced G→A mutation rate 
and resulted in drug resistant variants. However, the drug resistant variants resulting from 
APOBEC3-induced mutagenesis were less able to replicate than drug resistant viruses derived 
from RT-induced mutations alone. Altogether, the data support a model in which APOBEC3 
enzymes cooperate to restrict HIV-1, which ensures that viral inactivation is more likely to occur 
than viral evolution. 
2.2 Introduction 
In order to infect host cells, the Human Immunodeficiency Virus (HIV) must overcome the 
activity of several host restriction factors17,161. Due to the lifelong infection caused by HIV, there 
is extensive adaptation between the host restriction factors and their counteracting viral accessory 
proteins162-170. HIV restriction factors can prevent viral budding, decrease nuclear accumulation of 
viral cDNAs, interfere with reverse transcription and induce mutagenesis of proviral 
DNA17,161.While viral evolution to continually evade host restriction occurs constantly through 
selected mutations resulting from reverse transcriptase (RT) error there may also be a contribution 
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from a group of host restriction factors118,171-174. The APOBEC3 restriction factors of HIV can 
induce mutagenesis of proviral DNA by deaminating cytosine to form promutagenic uracil in (-) 
DNA when it is single stranded17,77,161. Copying of these uracils during (+) DNA synthesis results 
in guanine to adenine mutations17,77,161. The intensity of these mutations is dependent on both the 
activity of the APOBEC3 (A3) enzymes and the ability of the HIV protein Vif to suppress A3 
activity92.  
 The HIV-1 protein Vif mediates the proteasomal degradation of several human A3 
enzymes that are expressed in CD4 + T cells92,175. HIV-1 Vif interacts with the transcription 
cofactor CBF-β for stability and also interacts with the Elongin C and Cullin 5 components of a 
Cullin5 E3 ubiquitin ligase assembly27,176,177. Elongin C is an obligate heterodimer with Elongin 
B and Cullin 5 recruits Rbx2 to the complex27,176,177. This enables Vif, which replaces the human 
SOCS2 protein in this complex to act as the substrate receptor, to bring A3 enzymes in proximity 
to this complex178-180. This results in the polyubiquitination and degradation of A3 enzymes after 
Rbx2 recruits an E2 that transfers the lysine residues33,181,182. Without the action of Vif, higher 
numbers of A3 enzymes would bind HIV-1 genomic RNA or cellular RNA that is also bound by 
HIV-1 Gag and be encapsidated into virions117,183,184. Of the seven human A3 enzymes, A3C, A3D, 
A3F, A3G, and A3H interact with Vif, resulting in their proteasomal degradation185-190. Even if 
A3 enzymes escape Vif-mediated degradation, Vif can block encapsidation of A3s into virions by 
a degradation-independent mechanism and Vif can inhibit the activity of A3G when co-
encapsidated191-194. Despite the multi-modal action of Vif, A3-mediated mutagenesis of proviral 
genomes in HIV+ people occurs156,195-204. This may be due to fortuitous escape from Vif or that 
the ability of Vif to induce A3 degradation can decrease over the course of an infection119,120. 
Regardless of how A3 enzymes escape Vif-mediated inhibition, they remain within the 
capsid of the virus and exert their restriction activity in the next target cell that the virus infects. 
When the HIV-1 reverse transcriptase synthesizes the (-) DNA from the genomic RNA (gRNA) 
template, the RNase H domain becomes able to degrade the gRNA, exposing single-stranded 
regions of the (-) DNA77,205. A3 enzymes can only deaminate DNA when it is single stranded 
(ssDNA) and it has been demonstrated that more A3-induced mutations accumulate in proviral 
DNA in regions that are the last to become double-stranded. These vulnerable regions are on the 
5′-side of both the central and 3′ polypurine tracts (PPTs) and result in two gradients of 
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mutations206-208. The A3 enzymes combat this limited time of substrate availability by acting on 
ssDNA processively, which greatly increases the deamination efficiency of the enzymes77,92. Of 
the five A3 enzymes that can encapsidate into HIV-1 virions and are targeted by Vif, each have 
differing activity that can be discerned based on their respective levels of processivity77,92. In the 
absence of Vif, when A3 activity is at its highest, A3G can induce the most mutations and is the 
most processive77,92. As processivity declines so do deamination levels in ΔVif HIV-1 virions 
where A3H, A3F, and A3C show a decreasing gradient of activity after A3G77,92,131,133,135,209. There 
are also other factors that affect A3 activity, such as the polymorphisms present in the human 
population110-113,127,160,210-212. A3H exists as seven major haplotypes based on a combination of five 
polymorphisms, but only haplotypes II, V, and VII are stable in cells and can encapsidated into 
HIV virions and restrict HIV111,113. However, depending on the haplotype, only 1% (haplotype 
VII)111,113, 5-20% (haplotype V)111,113, or 6-27% (haplotype II)111,113,127 of the human population 
has an A3H genotype that can result in HIV restriction. An A3C polymorphism present in 10% of 
people of African descent enables A3C dimerization and processivity, resulting in HIV restriction 
ability 110,209. Another variable that has been identified to effect A3 restriction activity is the 
preferred deamination motif. A3G preferentially deaminates in 5′CC motifs on the (-) DNA 125. 
This results in 5′GG→5′AG mutations in the (+) DNA. This motif occurs in codons for the amino 
acids for tryptophan, glycine, aspartate, and glutamate and deamination of cytosines results in the 
formation of nonsense mutations for tryptophan codons or nonconservative amino acid changes 
for the other codons 77. The other A3s all prefer to deaminate 5′TC motifs on the (-) DNA, resulting 
in 5′GA→5′AA mutations in the (+) DNA77. These mutations result in a wide variety of missense 
mutations and can cause nonsense mutations, but nonsense mutations occur at least 2-fold less than 
from A3G deaminations, depending on the experimental system77,213. 
Since A3-mediated restriction is based on functional inactivation of proviral DNA, the 
number and type of mutations that an A3 enzyme induces is an important factor. Low levels of 
mutations or missense mutations may result in either HIV-1 evolution or have a neutral effect, 
rather than HIV-1 inactivation150,152,174,199,214-216. Studies have demonstrated that due to the A3G 
preferred deamination motif, A3G-mediated mutagenesis is likely to induce viral 
inactivation133,144,213,217-219. However, the A3s that cause 5′GA→5′AA mutations (A3F, A3H, and 
A3C) may be more likely to induce HIV-1 genetic diversity and evolution77,213,219. These data in 
combination with data demonstrating that during chronic HIV-1 infection Vif can acquire 
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mutations that partially decrease its ability to induce A3 degradation suggest that HIV-1 can 
manipulate A3 activity like a mutational rheostat119,120,150. Evidence of this has come from studies 
that have assessed antiviral drug resistance, CTL epitopes, and co-receptor usage, some of which 
used less effective Vif variants isolated from HIV+ individuals150,171,174,214,215,219. Studies support 
that A3G and A3F can influence the transition from usage of the CCR5 to CXCR4 coreceptor 
171,219. However, studies addressing how A3 enzymes impact CTL epitopes and antiviral drug 
resistance have resulted in mixed findings173,174,214,215,220-222. For CTL epitopes, data has 
demonstrated that A3-mediated mutagenesis can either enhance or decrease presentation of 
peptides on MHC receptors. Although some studies demonstrated that the majority of A3 mutated 
CTL epitopes result in decreased peptide presentation174, suggesting A3-mediated immune escape, 
other studies have demonstrated that the A3 mutated CTL epitopes bias the immune response 
against functionally inactivated viruses214. Thus, there may be a spectrum of effects depending on 
the A3 enzymes encapsidated and the functionality of Vif. 
 Similar to data obtained on A3-mediated immune escape, the studies assessing whether A3 
mediated mutagenesis can cause drug resistance have led to different conclusions. This may be 
because each study used a different cell-based experimental system. In Mulder et al., the authors 
used a less active Vif variant (K22H) isolated from an HIV+ individual to create a hypermutated 
virus population that was largely unable to replicate, but the integrated proviral genomes contained 
the M184I mutation in pol that confers resistance to the antiretroviral (ARV) drug 3TC 
(Lamivudine, 2′-deoxy-3′-thiacytidine)150. By co-infecting cells with a replication competent virus 
and the hypermutated ones, the authors were able to show that viral recombination could rescue 
replication in the presence of high amounts of 3TC150. The MT2 cell line used also expressed 
endogenous A3s, suggesting that A3 enzymes, even over multiple rounds of replication, can result 
in virus evolution 150. In contrast, a combined experimental and in silico study demonstrated that 
super-infection of cells and viral recombination between inactivated and competent virus is 
unlikely to occur and suggested that hypermutated proviruses are a dead-end 152. Nonetheless, the 
Vif K22H mutation correlated with increased virological treatment failure in HIV+ individuals, 
which may be due to increased levels of preexisting drug resistance mutations induced by A3 
enzymes, even though many of the proviral genomes may be nonfunctional120,223,224. However, 
none of these studies addressed if there could be drug resistance in a WT HIV-1 infection before 
A3 hypermutation was induced, which must occur since viral replication is maintained. Another 
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study addressed this and used CEM-SS cells that do not express A3s and created a CEM-SS cell 
line stably expressing A3G and showed with WT HIV-1 spreading infections that resistance to 
3TC only arose in the cells expressing A3G216. This study supports the hypothesis that Vif 
suppresses A3-mediated hypermutation, but still allows for a small enough number of mutations 
to occur that provides a benefit to the HIV-1 genetic diversity216. However, clinical studies have 
not found a significant correlation between A3 enzymes and HIV-1 drug resistance159,225-227. 
Namely, studies in which A3 enzymes were found to induce drug resistant mutations concluded 
that the contribution from A3 enzymes was so minor to the total viral population or that sequences 
with drug resistant mutations also contained stop codons suggesting that the A3 contribution was 
insignificant. These observations relate to the principle of purifying selection and that drug 
resistance mutations induced by A3 enzymes may have too many other collateral mutations to 
produce replication competent virus or be rescued by viral recombination152,228.  
 Overall, both the cell-based and clinical studies have not addressed several factors 
regarding this topic. First, HIV-1 reverse transcriptase (RT) also has a preference to cause G→A 
mutations and it has not been established whether the A3 sequence contexts of 5′GG or 5′GA can 
properly discriminate between A3- and RT- induced mutations90,148,229. Second, several studies 
have used “hypermutated” viruses due to the absence of Vif, use of less active Vif variants, or use 
of proviral DNA sequences from databases150,152,172, but the effect of A3s with a wild type (WT) 
HIV-1 and Vif are not known; in particular, we still do not know the average number of 
deaminations an A3 can induce in a single round of replication with WT HIV-1. Third, several 
studies have tested only A3G150,172,216 even though A3 enzymes are known to be coordinately 
expressed and A3F and A3G have been shown to interact as a hetero-oligomer that has enhanced 
HIV-1 restriction activity144,230,231. Here we assessed if the A3 enzymes A3F and A3G could cause 
drug resistance to develop in HIV-1. We chose to study A3F and A3G since they are most 
commonly the active A3s found in the human population212. We examined how the enzymes 
influenced drug resistance against 3TC and AZT (Azidothymidine, Zidovudine (ZDV)) each 
alone. Since drug resistance can easily develop with monotherapies, we also tested a mixed ARV 
regimen of TDF (Tenofovir Disoproxil Fumarate), 3TC, and EFV (Efavirenz) (TLE regimen). We 
found that the A3F/A3G hetero-oligomer enabled partial resistance of A3F to Vif-mediated 
degradation with a corresponding increase in A3F encapsidation and deaminations in the presence 
of Vif. Thus, even though A3F is less active than A3G in ΔVif HIV-1 studies, the combination of 
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the activities and differential sensitives to Vif leads to almost equal contributions to mutagenesis 
in WT HIV-1 infections. The resulting deaminations were above the RT-induced G→A mutation 
rate and resulted in drug resistant variants. However, the drug resistant variants resulting from A3-
induced mutagenesis were less able to replicate than drug resistant viruses derived from RT-
induced mutations alone. Altogether, the data support a model in which A3 enzymes cooperate to 
restrict HIV-1, which ensures that viral inactivation is more likely to occur than viral evolution. 
2.3 Material and Methods 
Spreading infection in PBMCs  
Healthy donor PMBCs were isolated from whole blood samples using Ficoll-Paque (GE-
Healthcare) density gradient centrifugation and SepMate-50 tubes (STEMCELL Technologies) as 
per manufacturer’s protocol. Cells were cultured in RPMI 1640 media (Hyclone) with 10% heat 
inactivated FBS (Gibco), and 1% PenStrep (Hyclone). Cells were stimulated for 3 days at 37°C 
with 10 ng/mL recombinant human IL-2 (Sigma) and 10 μg/mL Phytohemagglutinin-L (PHA-L) 
(Roche). Cells were then harvested and 8 x 105 cells/mL were dispensed to tubes and infected with 
0.05 MOI of WT HIVLAI. Cells were gently vortexed and incubated with the virus at 37°C for 16 
h. Next, the cells were pelleted at 300 x g for 2 minutes at room temperature. The supernatant was 
removed and the cells were washed twice with PBS. Cell pellets were resuspended in complete 
RPMI with IL-2 alone or containing a titration of either: AZT (6.25-50 μM), 3TC (9.38-150 μM) 
or a 1:2 to 1:32 dilution of the Mixed ARVs TDF, 3TC, and EFV with initial concentration of 100 
μM, 300 μM, and 1 μM, respectively. The cells were then dispensed into a well of a 24-well plate. 
This constituted day 0. Three days later 180 μL of supernatant was harvested and saved at -80°C 
and 180 μL was replaced to the well with its respective drug-containing media. Samples were 
taken every three days for the duration of twenty days. On day 21, the supernatant was harvested 
and applied to freshly stimulated PMBCs, prepared as described. This cycle continued until day 
30, when the final supernatant was removed and the cellular genomic DNA was harvested by 
DNAzol (Invitrogen) treatment, following manufacturer protocol, for provirus sequencing. The 
frozen virus aliquots were subsequently used for RT assay and viral RNA extraction for cDNA 
synthesis.  
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Spreading infection in CEM/CEM-SS 
Cells were cultured in RPMI 1640 media (Hyclone) plus 10% heat inactivated FBS (Gibco) 
medium containing 1% PenStrep (Hyclone). For stimulation, 10 ng/mL human IL-2 (Sigma) and 
10 μg/mL PHA-L (Roche) was incubated with cells for 3 days. Cells were then harvested and 8 x 
105 cells/mL and were dispensed to tubes and infected with 0.25 MOI of WT HIVLAI. The 
spreading infection then progressed as described for PBMCs. Samples were taken every three days 
for the duration of thirty days. The final supernatant was removed and the cellular genomic DNA 
was harvested by DNAzol (Invitrogen) treatment, following manufacturer protocol, for provirus 
sequencing. The frozen virus aliquots were subsequently used for RT assay and viral RNA 
extraction for cDNA synthesis. 
Spreading infection in U87 CD4+ CXCR4+ cells 
Cells were cultured in DMEM (Hyclone) +10% FBS (Gibco). For spreading infections, 1 
x 105 cells in 1 mL were plated in each well of a 12 -well plate and infected with 0.01 MOI of WT 
HIVLAI with or without encapsidated A3F/A3G. Then, 16 h post infection, the media was replaced 
with 1.5 mL of DMEM+10% FBS and 1% PenStrep (Hyclone) alone or containing a dilution of: 
AZT (6.25-50 μM), 3TC (9.38-150 μM) or 1:2 to 1:32 dilution of the Mixed ARVs TDF, 3TC, 
and EFV with initial concentration of 100 μM, 300 μM, and 1 μM, respectively. Three days later 
180 μL of supernatant was harvested and saved at -80° C and 180 μL of appropriate media was 
replaced to the well. Samples were taken every three days for the duration of thirty days. The 
cellular genomic DNA was harvested by DNAzol (Invitrogen), following manufacturer protocol, 
treatment for provirus sequencing. The frozen virus aliquots were subsequently used for RT assay 
and viral RNA extraction for cDNA synthesis. 
Single cycle infectivity assay 
HIV-1LAI Δvif Δenv or HIV-1 LAI Δenv (500 ng) were cotransfected into 1 x 105 293T 
cells with 25, 50, or 100 ng of A3G in MCS-II of pVIVO2 (Invivogen) vector with a C-terminal 
HA tag, A3F in MCS-I of pVIVO2 vector with a C-terminal V5 tag, A3F/A3G where A3F was 
cloned into MSC-I of pVIVO2 with a C-terminal V5 tag and A3G was cloned into the MCS-II of 
the pVIVO2 vector with a C-terminal HA tag, or Empty pVIVO2 vector. Construction of these 
vectors has been previously described 144. GeneJuice (Novagen) transfection reagent was used as 
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per manufacturer’s protocol and cells were maintained in DMEM supplemented with 10% FBS. 
After 20 h the media was changed and 48 h post transfection the virus-containing supernatants 
were harvested and filtered through a 0.45 μm polyvinylidene difluoride (PVDF) syringe filter. 
The cells were washed with PBS, lysed in Laemmli buffer and used for immunoblotting. For the 
infectivity assay, 1 x 104 of HeLa CD4+ CCR5+ LTR lacZ cells per well of a 96-well plate were 
infected with a serial dilution of HIVLAI Δvif Δenv or HIVLAI Δenv virus in the presence of 8 μg/mL 
of Polybrene. At 48 h post infection infectivity was measured through a colorimetric detection 
using a β-galactosidase assay reagent (Pierce). Infectivity of each virus was compared by using 
the infectivity of the No A3 condition as 100%. 
Immunoblotting 
Tagged proteins in cells or virions were detected by rabbit anti-HA (1:1000, Sigma) or 
rabbit anti-V5 (1:500, Sigma). Mouse anti-α tubulin (1:1000, Sigma) and anti-p24 (1:1000, Cat# 
3537, NIH AIDS Reagent Program) were used to detect the cell lysate loading control (α-tubulin) 
and the virus lysate loading control (p24). For cell lysates, 40 μg total protein was used. For virions, 
a portion of the filtered supernatant was concentrated using Retro-X concentrator (Clonetech) 
according to manufacturer’s instructions and 20 μL was used.  
Genotyping PBMCs and CEM cells 
The A3F polymorphic sites were amplified using PCR. The presence of the polymorphism 
that results in S108A was determined using the following primers: (forward) 5′ 
GTGATATCCCAGCCTGAGCA and (reverse) 5′ CTTCATCGTCCATAATCTTCACG. The 
presence of the polymorphism that results in I231V was determined using the following primers 
(forward) 5′ AGCCTATGGTCGGAACGAAA and (reverse) 5′ CTGGTTTCGGAAGACGCC 
primers. The PCR amplification used Q5 High Fidelity polymerase (New England Biolabs) and 
cycling conditions were 98° C for 30 sec followed by 30 cycles of 98° C for 10 sec, 64-67° C for 
20 sec, 72° C for 20 sec and 2 minutes at 72° C. Amplicons were cloned using the CloneJET PCR 
cloning kit (ThermoScientific) as outlined in the manufacturer’s protocol. Analysis for A3F S108A 
and A3F I231V polymorphisms included 6-12 clones for each position from PBMCs and CEM 
cells to determine zygosity. 
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Vif degradation assay 
To compare efficiency of Vif in mediating degradation of A3F, A3G and A3F/A3G, 1 x 
105 293T cells per well of a 12-well plate were co-transfected with 50 ng of A3F-V5, A3G-HA, 
A3F-V5/A3G-HA or empty pVIVO2 (No A3) and a titration of VifLAI expression plasmid (0,10, 
25, 50, 100, and 200 ng). GeneJuice (Novagen) used as transfection reagent as described by the 
manufacturer. DMEM and 10% FBS was used to maintain the cells. Twenty hours post 
transfection the media was changed and 48 h post transfection cells were washed in PBS and lysed 
with Laemmli buffer. Vif was detected with HIV-1 Vif monoclonal antibody (1:1000; Cat# 6459, 
NIH AIDS Reagent Program) and immunoblotting was carried out as described for cell lysates.  
RT assay 
To measure the viability of the virus we performed a RT assay. The assay relates the 
functional activity of RT to the level of infection. The assay used 10 μL of supernatant in duplicate. 
RT buffer (25 mM Tris pH 7.8, 37.5 mM KCl, 2.5 mM MgCl2, 0.25% v/v NP-40, 0.025 U Poly 
rA p(dT) 12-18, and 1 mM DTT) was used to lyse virions and provide the DNA template. The 
reaction was incubated for 20 minutes at room temperature for lysis. Then, α-32P-TTP 
(800Ci/mmol), diluted in RT buffer, was added to each sample and incubated for 2 h at 37°C. 
Afterwards, the mixture was spotted onto a Whatman DE81 paper (Perkin Elmer) and dried for 10 
minutes. This was followed by washing in SSC buffer and 85% ethanol. The paper was then dried 
for 10 minutes at 65°C and exposed overnight to a phosphoimaging screen. The screen was 
scanned on a Typhoon Trio Imager and the file was analyzed with Image Quant Software. Purified 
RT of known concentration was used in the assay to construct a standard curve, which was used 
to determine the RT concentration in the culture supernatants. The standard curve is shown in 
Figure 2.1H. 
Deep Sequencing 
HIV genomic RNA was purified from the supernatant of infected cells using QIAamp Viral 
RNA Kit (Cat# 52904) as per manufacturer’s protocol. The cDNA was synthesized using only the 
Half RT reverse primer (Table 2.3) and AccuScript High Fidelity Reverse Transcriptase (Agilent). 
From the virus cDNA, pol nucleotides 1792-3536 was amplified by PCR with Pfu polymerase 
(Agilent) using Ext F p7.9 forward primer and Half RT reverse primer (Table 2.3). The product of 
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this reaction was then amplified (1807-3463 nt) in a nested PCR reaction with Pfu using Ext F 
p7.10 forward primer and Half Pol reverse primer. Primers are listed in Table 2.3. Proviral DNA 
was obtained by using DNAzol Reagent (Invitrogen) as described in the manufacturer’s protocol. 
The extracted DNA was then treated with DpnI (NEB) for 1 hour at 37°C to digest any 
contaminating transfected plasmid. 
The region to be sequenced for both cDNA and proviral DNA was pol nucleotides 2573-
3301 nt and was divided into three 360 nt overlapping segments. All segment PCR reactions were 
performed with Q5 polymerase (NEB) Segment 1 (2573-2933 nt) was amplified using primers 
D67N_F forward and D67N_R reverse primers. Segment 2 (2789-3149 nt) was amplified using 
primer E138K_F forward and E138K_R reverse primers. Segment 3 (2941-3301 nt) was amplified 
using primer M184I_F forward and M184I_R reverse primers. Primers are listed in Table 2.3. For 
use in the Illumina MiSeq we performed another PCR with the segments cognate MS primer to 
add the necessary overhang adapter sequences. The amplicons were then sequenced following the 
16S Metagenomic Sequencing Library Preparation manual (Illumina) using the reagent described. 
Prepared samples were sequenced using MiSeq Nano V2 chemistry in a 250x250 paired-end 
reaction. 
Deep Sequencing Analysis 
Illumina data was processed through a custom code to remove poor quality reads. The data 
was formatted to the base substitutions in a dinucleotide context. The data once in this form was 
analyzed with a custom excel code to determine the level of deamination in an A3 relevant 
dinucleotide context. Overall deamination frequencies were derived by adding all the in-context 
deaminations for a sample across all three segments and dividing the sum by the total number of 
nucleotides sequenced (across all three segments). 
2.4 Results 
2.4.1 Co-expression of A3G and A3F results in partial protection of A3F from Vif-mediated 
degradation 
In the absence of Vif, A3G and A3F have different abilities to restrict HIV-1. In single-
cycle infectivity assays, across a range of transfected A3 plasmid, A3F restricts ΔVif HIV-1 6- to 
10- fold less than A3G (Figure 2.1A). However, both A3G and A3F are suppressed by Vif in a 
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single-cycle infectivity with WT HIV-1, as demonstrated by high HIV-1 infectivity levels (Figure 
2.1B). To more accurately assess the impact of A3G and A3F, which are coordinately expressed 
in CD4+ T cells and hetero-oligomerize, we used a vector with two multiple cloning sites so that 
on a per cell basis each transfected cell would express both A3G-HA and A3F-V5. Under these 
conditions, the ΔVif HIV-1 restriction by hetero-oligomerized A3F and A3G was equal to that of 
A3G alone (Figure 2.1A) and the WT HIV-1 appeared to be able to suppress both A3G and A3F 
(Figure 2.1B). To track the A3G and A3F we immunoblotted cell and virus lysates from the 
infectivity experiment. The A3G-HA was sensitive to Vif-mediated degradation, resulting in less 
A3G encapsidation in the presence of Vif, although A3G was still present in cells infected with 
WT HIV-1 (Figure 2.1C). In contrast, the A3F-V5 was not detected in cells or viruses in the 
presence of Vif (Figure 2.1D). Upon co-expression of A3G and A3F, we found no change in A3G 
sensitivity to Vif-mediated degradation or encapsidation, but there was a change in A3F protein 
levels (Figure 2.1C-D). In ΔVif HIV-1 infected cells, the co-expression of A3G with A3F 
stabilized the steady state level of A3F in cells and resulted in 2-fold more A3F being encapsidated 
(Figure 2.1D). During a WT HIV-1 infection, the presence of A3G resulted in incomplete 
degradation of A3F and resulted in A3F encapsidation (Figure 2.1D). Despite the hetero-
oligomerized A3s being encapsidated in the presence of Vif, there was no significant effect on 
viral infectivity (Figure 2.1B). For A3G, this is likely due to degradation-independent Vif-
mediated inhibition of A3G deamination activity. Vif binds A3G on N-terminal domain (NTD) 
loop 7 that is also required for A3G processivity, resulting in less efficient deamination during 
reverse transcription193,194. This is unlikely to occur for A3F since Vif binds A3F in the C-terminal 
domain (CTD), which is not required for A3F processivity. However, A3F is also less active than 
A3G, making the contribution of A3F encapsidated during a WT HIV-1 infection unclear. To 
determine the extent that A3F is protected from Vif-mediated degradation when co-expressed with 
A3G, we co-expressed the A3s with different amounts of Vif expressed from a plasmid, rather 
than the HIV-1 genome. We determined that A3F was more sensitive to Vif-mediated degradation 
than A3G (Figure 2.1E-F). When co-expressed with A3G, the A3F was not sensitive to Vif-
mediated degradation whereas A3G degradation was the same as when A3G was expressed alone 
(Figure 2.1G). Altogether, these results demonstrate that there is not complete Vif-mediated 
degradation of A3F when it is co-expressed with A3G. These data prompted us to determine the 
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A3-induced mutation frequency of HIV-1 proviral DNA in the presence of Vif, since it may have 
been previously underestimated due to the use of single A3s.  
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Figure 2.1 Coexpression of A3G and A3F results protection of A3F from Vif mediated 
degradation. (A) In a ΔVif HIV-1 single-cycle infectivity experiment, A3G and coexpressed A3F 
and A3G (A3F/A3G) restrict viral replication more than A3F alone. (B) In a HIV-1 single-cycle 
infectivity experiment A3G, A3F, and A3F/A3G are suppressed by Vif. (A-B) Data were produced 
from three independent experiments and error bars represent the standard deviation from the mean. 
(C-D) Immunoblots from the samples used in panels A and B. (C) Vif induces degradation of HA-
tagged A3G when expressed alone or coexpressed with V5-tagged A3F. (D) Vif induces 
degradation of V5-tagged A3F, but A3F is partially rescued from degradation when expressed in 
the presence of HA-tagged A3G. (E-G) Further analysis of the A3G-mediated protection of A3F 
from Vif was carried out using increasing amounts of Vif expression plasmid that was 
cotransfected with a constant amount of (E) HA-tagged A3G, (F) V5-tagged A3F, and (G) co-
expression of the HA-tagged A3G and V5-tagged A3F (A3F/A3G). The data show that A3F, but 
not A3G is protected from Vif mediated degradation when A3F and A3G are coexpressed. (E-G) 
Immunoblots were conducted from three independent experiments and a representative blot is 
shown.  
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2.4.2 Level of A3G and A3F induced G→A mutations exceed those of RT in a single cycle 
HIV-1 infection 
To determine the maximum numbers of A3-induced mutations during a WT HIV-1 
infection we amplified the pol (nt 2110-2862) from proviral DNA of single-cycle infectivity 
experiments using 25 ng transfected A3 plasmid and sequenced the amplicons on an Illumina 
MiSeq platform (Figure 2.2A). The sequences were processed through a custom code to determine 
the flanking nucleotides of deaminations (see Materials and Methods). The proviral DNA was 
analyzed for the G→A mutation frequency in the presence and absence of Vif. In the absence of 
A3 enzymes and in the presence or absence of Vif, the RT rate of G→A mutations stayed relatively 
the same and was ~0.5 mutations/kb (Figure 2.2B). In the absence of Vif, both A3F and A3G 
induced high numbers of mutations with A3F inducing 5.6 mutations/kb and A3G inducing 14 
mutations/kb (Figure 2.2B). From these values, we defined A3-induced G→A hypermutation as 
being at least 10-fold above the RT G→A mutation rate. In the presence of Vif, the A3F-induced 
mutations were not significantly different from the no A3 condition, consistent with the 
immunoblot that showed no detectable A3F encapsidation in the presence of Vif (Figure 2.2B, 0.5 
mutations/kb). In the presence of Vif, A3G was able to induce 2.1 mutations/kb, although this 
appeared not to have any significant effect on the infectivity level of the HIV-1 (Figure 2.2B and 
Figure 2.1B). When A3F and A3G were coexpressed in the absence and presence of Vif, the 
mutation frequency was similar to A3G alone and was 11 mutations/kb and 1.8 mutations/kb, 
respectively (Figure 2.2B). These data indicate that in a WT HIV-1 infection, the A3s can induce 
a mutation frequency in proviral DNA that is ~4-fold above RT in a single-cycle of replication and 
suggest that hypermutated proviral DNA isolated from HIV+ people was exposed to A3s over 
multiple rounds of infection.  
 To determine which A3 was inducing the G→A mutations, we further analyzed the 
sequencing data to determine the GG→AG and GA→AA mutation frequencies. Since A3G 
deaminates within 5′CC contexts, the (+) DNA mutations are GG→AG. This are discernable from 
A3F deaminations that occur within 5′TC contexts that result in (+) DNA mutations that are in the 
GA→AA context. Analysis of the ΔVif HIV-1 condition demonstrates that the random RT 
mutations that fall into an A3 context are equivalent to the total RT-induced G→A mutations, 
demonstrating that in context G→A mutations a priori cannot solely be attributed to A3 
deamination activity (Figure 2.2B). The A3F-induced mutations are 91% in the GA→AA context 
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(Figure 2.2B). The A3G-induced mutations are less stringent with the preferred GG→AG context 
being mutated 79% of the total (Figure 2.2B). In the WT HIV-1 condition when each A3 is 
expressed alone the A3F-induced mutations are 69% in the GA→AA context and the A3G-induced 
mutations are 87% in the GG→AG context (Figure 2.2B). In the ΔVif HIV-1 condition with 
combined A3F/A3G expression, the GA→AA mutations and GG→AG mutations were similar to 
A3G alone (Figure 2.2B, A3F/A3G has 2.8 GA→AA and 8.5 GG→AG mutations/kb), likely due 
to high A3G activity that can obscure the cooperative effects of coencapsidated A3F/A3G 144. In 
the WT HIV-1 condition, the mutations induced by the combined expression of A3F/A3G results 
in a 60/40% split between GG→AG/ GA→AA mutations with the total amount of GA→AA 
mutations being more than when A3F or A3G were expressed alone (Figure 2.2B). This was 
consistent with Vif-mediated degradation data that showed A3F can be partially rescued from Vif 
mediated degradation in the presence of A3G (Figure 2.1E). Altogether, the data demonstrated that 
the combined expression of A3G and A3F resulted in a combined effect of both A3s on proviral 
mutagenesis in the presence of Vif, likely due to the ability of A3G and A3F to form a hetero-
oligomer144.  
2.4.3 A3F and A3G can induce drug resistance mutations in proviral DNA 
We next determined the nature of the mutations in the proviral DNA to establish whether 
A3F and A3G could contribute to preexisting drug resistance mutations in proviral DNA. We 
examined several drug resistance changes along the pol gene and noted a significant increase in 
mutations from 5′→3′ in the (+) DNA, consistent with gradients of mutations forming in proximity 
to polypurine tract (PPT) regions206-208. The HIV-1 central PPT (cPPT) is within pol, with 
mutations peaking directly before the cPPT and within pol. We examined two types of possible 
mutations, those that contain an A3 deamination motif in the codon, which correspond to drug 
resistant mutations D67N, M184I, E138K, and G190R/E (Table 2.1). We also determined the level 
mutations that can only be induced by RT, such as K65R, T215Y/F, K103S/N, and Y118L/C/H to 
determine if the ability of A3s to interfere with RT polymerization also effects its insertion fidelity 
(Table 2.1). We used the ‘No A3’ transfection condition to represent the RT induced mutations. In 
the absence of Vif, A3F was able to induce the D67N mutation 2-fold, the M184I mutation 7-fold, 
the E138K mutation 11-fold, the G190R 6-fold, and the G190E 15-fold more than RT. In contrast, 
in the absence of Vif, A3G preferentially caused mutations more than RT at E138K (23-fold more 
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than RT), M184I (108-fold more than RT), G190R (74-fold more than RT), and G190E (2-fold 
more than RT), but the D67N mutations were not significantly different from the no A3 condition 
(Figure 2.2C-F). When the A3F and A3G were coexpressed in the absence of Vif, the mutation 
pattern matched both A3F and A3G alone indicating that the hetero-oligomerization and 
coencapsidation of A3F and A3G did not alter their deamination preferences (Figure 2.2C-F). For 
A3F in the presence of Vif, only the D67N mutations (3.5-fold) and G190E (2-fold) were 
significantly mutated in comparison to the No A3 condition (Figure 2.2C-F). For A3G in the 
presence of Vif, there were more mutations induced than for the No A3 condition at the M184I 
site (3-fold), E138K site (1.3-fold), and G190R (2.8-fold) (Figure 2.2C-F). When A3F and A3G 
were coexpressed, only the mutations at the D67N site (1.2-fold more than RT), M184I site (2-
fold more than RT), G190R site (1.6-fold more than RT) and G190E site (9.5-fold more than RT) 
were preferentially mutated (Figure 2.2C-F). Altogether, these data suggest that in a WT HIV-1 
infection, A3G preferentially creates the M184I and G190R mutations and A3F preferentially 
creates the D67N and G190E mutations. 
 We also analyzed if drug resistant mutations that can only be induced by RT error, since 
they do not have cytosines in the (-) DNA sequence of the codon, were present in proviral DNA. 
We found that RT could induce mutations at K65R, K103S/N, Y188C/H/L, and T215F/Y, among 
others (Figure 2.2G-J. For the K103S/N, Y188C/H/L, and T215F/Y mutations, the No A3 
condition in the absence or presence of Vif had similar levels of these mutations (Figure 2.2G-J). 
However, for the K65R, the presence of Vif resulted in a 14-fold increase in the frequency, but 
overall this mutation occurred at a low level (Figure 2.2F, 4x10-5, -Vif; 6x10-4, +Vif). In Δ Vif 
condition the K65R mutation in the presence of A3F, A3G or A3F/A3G had 6- to 8- fold increase 
(Figure 2.2G). This effect on the K65R mutation was not observed in the presence of Vif (Figure 
2.2G). For the K103S/N mutation, the presence of A3G, either in the absence or presence of Vif 
resulted in an absence of the K103S mutation, although the K103N mutation was not changed 
(Figure 2.2H). For the Y188C/H/L mutation, the presence of A3G in the absence of Vif resulted 
in 5-fold less Y188C mutations (Figure 2.2I). However, in the presence of Vif, A3F, A3G, and 
A3F/G all caused changes in the mutation frequencies. The presence of A3F or A3G decreased the 
amount of Y188L mutations 3-fold (+Vif, A3F) to 7.5-fold (+Vif, A3G) and increased the amount 
of Y188H mutations by 1.8-fold (+Vif, A3F and A3G) (Figure 2.2I). The A3F/A3G condition 
resulted in 2-fold less Y188C mutations (Figure 2.2H). In the presence of Vif, for the T215F/Y 
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mutation, the presence of A3F resulted in a 2-fold increase in the mutation rate (Figure 2.2J). Since 
the (-) DNA sequence for these codons have no cytosines, these data suggest that either the 
physical inhibition of RT by A3 enzymes or nearby A3-catalyzed uracils can influence the RT 
insertion fidelity. However, these experiments were done in the absence of drug selection, so we 
sought to test which mutations were selected for in the presence of drug. 
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Figure 2.2 Drug resistant mutations can be induced by A3-mediated mutations and RT-
induced error in a single round of virus replication. (A) Proviral DNA resulting from single 
cycle infectivity assays from Figure 2.1 was used as a template to PCR amplify 1011 nt of pol 
(2085-3096), which was further amplified with nested primers that contained Illumina adapters, 
resulting in a total 762 nt region of pol that was analyzed by next-generation sequencing. The 762 
nt was amplified as three separate segments. (B) The G→A mutations in both the GA→AA (A3F 
context) and GG→AG (A3G context) were determined from ΔVif and WT HIV-1 infections. (C-
E) Drug resistant mutations that can be induced by A3-mediated mutagenesis due to a deamination 
motif within the (-) DNA sequence. Note that not all y-axis scales are the same due to different 
mutation frequencies imposed by the timing of (+) DNA synthesis. (C) The D67N mutation was 
preferentially induced by A3F. (D) The E138K mutation was induced by A3F and A3G in ΔVif, 
but not WT HIV-1 infections. (E) The M184I mutation was preferentially induced by A3G. (F-I) 
Drug resistance mutations that can only result from RT-induced error. The RT-indcued errors 
resulted mutations at (F) K65R, (G) K103S/N, (H) Y188C/H/L, and (I) T215F/Y. Drug resistant 
mutations relevant to the drug resistance selection experiments are shown.  
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2.4.4 Drug resistant HIV-1 can be selected for from spreading infections of PBMCs 
 The A3G and A3F could contribute to drug resistance mutations in the absence of Vif and 
any drug selection, but with mutation rates of 4 mutations/kb even in the presence of Vif there 
would be a chance that the A3s would induce enough mutations to inactivate the virus. Despite 
this, there is evidence that inactivated drug resistant viruses can be rescued, if they are 
transcriptionally active, through viral recombination of two distinct genomic RNAs150. As a result, 
we determined if these mutations could cause viral growth in the presence of ARVs with 
endogenously expressed A3s from PBMCs. A3F commonly occurs as two polymorphisms, 
108S/231I and 108A/231V160,212. The donor genotype for A3F was 108S/231I, which was the same 
A3F in the molecular clone used for single-cycle infectivity assays (Figure 2.1 and Figure 2.2). 
The selection of drug resistant virus used a two-fold serial dilution of the ARV, either AZT (6.25-
50 μM), 3TC (9.38-150 μM), or the Mixed ARVs (TDF, 3TC, and EFV; TLE regimen) (Figure 
2.3A). Mutations conferring resistance to AZT (D67N) and 3TC (M184I) can directly arise from 
A3-mediated mutagenesis (Figure 2.2C, D and Table 2.1). In the Mixed ARVs, the 3TC resistance 
(M184I), EFV resistance (primarily K103S/N, Y188L/C/H, and G190E/R), and TDF resistance 
(K65R) can arise from a combination of RT- and A3- mediated mutagenesis (Figure 2.2D-H). For 
A3-mediated mutations, only the M184I and G190E/R mutations are possible (Table 2.1). After 
infection of PBMCs with WT HIV-1LAI, the RT activity in supernatants was measured every third 
day and used to detect if virus was present. The growth took place over 30 days with the total viral 
supernatant being added to fresh PBMCs from the same donor at day 21. The normal growth of 
HIV-1 in the PBMCs resulted in a peak at day 12 (Figure 2.3B). Proviral DNA was isolated for 
sequencing at day 30 and genomic RNA was isolated for cDNA synthesis and sequencing at the 
peak of virus replication.  
In the absence of any ARV drugs, the PBMCs accumulated drug resistance mutations. The 
highest levels of mutations in the proviral DNA were at K103N and G190E, conferring resistance 
to EFV (Figure 2.3C). The gRNA had corresponding K103N and G190E mutations, although the 
G190E was significantly lower in gRNA consistent with the principle of purifying selection since 
G190E has been reported to create an aberrant protease cleavage site232. Mutations at other sites 
such as M184I and D67N that can be induced by A3G and A3F, respectively, were also present, 
consistent with the single-cycle infectivity data showing the preexistence of drug resistance 
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mutations (Figure 2.3C, Figure 2.2E, G). When the HIV-1 was grown in the presence of ARVs, 
growth curves with delayed peaks were detected, but with approximately 10-fold less virus than 
in the absence of drug, consistent with low level variants emerging from the culture (Figure 2.3B 
and Figure 2.3D, F, H).  
Each ARV selected for a unique combination of drug resistance mutations. The HIV-1 
resistance to 3TC occurred at 75 μM 3TC and correlated with high levels of the M184I mutation 
in gRNA (Figure 2.3D-E). The G190E mutation was much higher, despite not being required for 
3TC resistance, but suggests that G190 was a hot spot for mutation either by RT or A3s. The HIV-
1 resistance to AZT occurred at 12.5 μM AZT and resulted in a similar growth curve, but with a 
more delayed peak of RT activity compared to growth with 3TC (Figure 2.3F, day 21 compared 
to day 15). The high level of resistance to AZT conferred by the T215F/Y (RT induced mutation) 
and D67N (A3F induced mutation) was observed at low levels in culture likely due to the selection 
of drug resistant variants at a low concentration of AZT (Figure 2.3E). Consistent with the M184I 
mutation causing increased sensitivity to AZT, the mutation was found in the proviral DNA at a 
much greater extent than in the gRNA (Figure 2.3E). The Mixed ARVs should select for resistance 
mutations at K65R, M184I, and any of the following K103S/N, Y188L/C/H, and G190E/R. At the 
1:2 dilution, we recovered resistant virus that had mutations at K65R, M184I, and K103S (Figure 
2.3H-I). The G190R was present at high amounts in proviral DNA but was 3-fold less likely to be 
in gRNA compared to the K103S (Figure 2.3I and inset). Consistent with M184I conferring 
increased sensitivity to TDF, there was a much higher amount of M184I mutations in the proviral 
DNA, than the gRNA (Figure 2.3I and inset). Altogether, the data from virus growth on infected 
PBMCs with and without drug selection demonstrated that this experimental system could be used 
to isolate drug resistant viruses and recover drug resistant mutations through deep sequencing. 
However, the data did not enable us to interpret the contribution of A3 enzymes to the emergence 
of drug resistant viruses or if A3s could induce the emergence of replication competent drug 
resistant viruses in a single round of replication. 
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Table 2.1 HIV-1 nucleotide and non-nucleotide reverse transcriptase inhibitors and 
possible resistance mutations. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
Drug resistant mutations are listed in bold face type if they are associated with the highest levels 
of resistance, mutations in italics contribute to resistance, and mutations in plain type contribute 
to resistance in combination with other resistance mutations. Data from the Stanford University 
HIV Drug Resistance Database. 
2
The probable APOBEC3 is based on the preferred sequence context for deaminase activity in the 
viral (-) DNA which is 5′TC for A3F and 5′CC for A3G.  
Drug 
Class Drug 
Primary Drug 
Resistance 
Mutations
1 
Possible A3-
induced 
Mutation 
Codon in (+)/ (-) 
DNA 
Probable 
APOBEC3
2 
NRTI (3TC) 
Lamivudine 
K65R 
M184I/V M184I 5′ATG/3′CAT A3F or A3G 
 Abacavir 
Didanosine 
K65R 
K70E 
L74V/I 
Y115F 
M184I/V 
M184I 5′ATG/3′CAT A3F or A3G 
  Tenofovir (TDF) 
Stavudine 
M41L 
K65R 
D67N 
K70E/R 
L210W 
T215Y/F 
D67N 5′GAC/3′CTG A3F 
 Zidovudine (AZT) 
M41L 
D67N 
K70R 
L210W 
T215Y/F 
D67N 5′GAC/3′CTG A3F 
NNRTI Etravirine 
Rilpivirine 
L100I 
K101E/P 
E138A/G/K/Q 
Y181C/I/V 
Y188L 
G190E 
M230L 
E138K 
G190E 5′GAA/3′TTC A3F 
  Nevirapine 
Efavirenz 
L100I 
K101E/P 
K103N/S 
V106A/M 
Y181C/I/V 
Y188L/C/H 
G190A/S/E 
M230L 
G190E 5′GGA/3′TCC A3G 
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Figure 2.3 Drug resistant HIV-1 can be isolated from infected PBMC cultures. (A) PBMCs 
were cultured for 30 d in with no drug or in the presence of increasing amounts of 3TC (9.38-150 
µM), AZT (6.25-50 µM), or Mixed ARVs. (B) Virus replication was measured using an RT assay 
and showed that the virus replication peaked in the PBMC culture at day 12. Drug resistant variants 
were also isolated, although the level of virus in the supernatant determined by the RT assay was 
approximately 10-fold less. (C) Drug resistance mutations were present in both provirus DNA and 
virus gRNA. (D) Virus resistant to 75 µM 3TC shown in panel A, but on an expanded scale. (E) 
Virus resistant to 3TC had the corresponding drug resistance mutation at M184I in gRNA, along 
with drug resistance mutations for other ARVs. (F) Virus resistant to 12.5 µM AZT shown in panel 
A, but on an expanded scale. (G) Virus resistant to AZT had the corresponding drug resistance 
mutations at D67N and T215F/Y, along with drug resistance mutations for other ARVs. (H) Virus 
resistant to a 1:2 dilution of Mixed ARVs (TDF, 3TC, EFV) shown in panel A, but on an expanded 
scale. (I) Virus resistant to TDF, 3TC, and EFV had corresponding mutations in K65R, M184I, 
and K103S/N, respectively, along with drug resistance mutations for other ARVs. 
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2.4.5 Exposure of HIV-1 to A3F and A3G in a single-cycle of replication produces AZT 
resistant viruses 
We next investigated if exposure to A3F and A3G in a single round of replication could introduce 
drug resistant mutations in otherwise replication competent viral genomes. For this experiment, 
we used U87 CD4+ CXCR4+ cells and infected them with HIV-1LAI. Two stocks of HIV-1LAI 
were prepared, one stock was produced in the presence of A3F and A3G so that the A3s were 
encapsidated into the virions (see Materials and Methods). The other stock was produced in the 
absence of A3F and A3G. Infection of U87 CD4+ CXCR4+ cells with these virus particles would 
result in A3 mediated mutagenesis occurring only in the first round of reverse transcription and 
proviral DNA synthesis, but the cultures were kept for 30 days to determine the fate of the A3 
induced mutations on drug resistance to AZT, 3TC, and the Mixed ARV TLE regimen (Figure 
2.4A). In the absence of any ARVs, the RT activity of the U87 CD4+ CXCR4+ cells under both 
No A3 and A3F/A3G conditions had similar profiles and peaked at day 6 (Figure 2.4B). 
Sequencing of the proviral DNA and cDNA produced from gRNA demonstrated the existence of 
drug resistant mutations, particularly M184I, K103S/N, and G190R/E (Figure 2.4C-D). The 
mutation profiles of the No A3 and A3F/A3G condition were very similar, suggesting that the 
majority of mutations were made from RT-induced error or that RT and A3F/A3G have 
overlapping mutational hot spots (Figure 2.4C-D).  
To discern the impact of RT and A3F/A3G, we conducted 4 independent experiments for 
U87 CD4+ CXCR4+ cells grown in the presence of 3TC or AZT. The experiments were then 
scored for whether drug resistance viruses were obtained and if it occurred in the No A3 or 
A3F/A3G condition (Table 2.2). We found that for 3TC resistance, out of 4 experiments, 3TC 
resistance arose once in the No A3 condition and once in the A3F/A3G condition (Table 2.2). 
Although the drug resistant variants that grew from viruses that had packaged A3F/A3G arose 
early at day 9, they could not maintain growth in culture and by day 12 the RT activity in the 
supernatant was lost (Figure 2.4E). In addition, the 3TC resistance was at 18.7 μM, less than the 
75 μM that arose in the PBMC culture (Figure 2.3D and Figure 2.4E). In contrast, the virus that 
had no A3 packaged resulted in robust drug resistant viruses emerging from the culture at day 18 
in the presence of 75 μM 3TC (Figure 2.4B). Accordingly, the drug resistant viruses from the No 
A3 condition had very high levels of the M184I mutation in proviral and cDNA isolated from 
gRNA (Figure 2.4F). In contrast the A3F/A3G exposed viruses had lower amounts of the M184I, 
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although the mutation was present in cDNA produced from gRNA (Figure 2.4G). The 3TC 
resistance is also strengthened by the K65R mutation, which can only be induced by RT and was 
also found in the A3F/A3G condition (Figure 2.4G). Consistent with the D67N mutation being a 
hot spot for A3-induced mutagenesis in the presence of Vif, this mutation was found at the highest 
amount in the proviral DNA, but not in the viral cDNA since there was no AZT selection (Figure 
2.4G). When the experiments did use AZT, the only conditions that did produce drug resistant 
virus was the condition with packaged A3F/A3G where we isolated drug resistant virus for two of 
the four experiments (Table 2.2). Although we recovered virus in one experiment for the No A3 
condition in the presence of AZT, the RT activity was 2.5-fold less than the A3F/A3G condition 
and we were unable to amplify the virus, which was required to isolate gRNA for cDNA synthesis 
and sequencing (Figure 2.4H). The sequencing data from the A3F/A3G condition in the presence 
of 12.5 μM AZT showed that the main mutation mediating the resistance was D67N (Figure 2.4I). 
Although the T215F/Y mutation that results in stronger AZT resistance was found in gRNA, the 
D67N mutation was 2.4-fold more frequent, consistent with A3F-mediated mutagenesis (Figure 
2.2C and Figure 2.4I). Altogether, these data suggest that 3TC resistance from the M184I mutation 
is more likely to occur from RT error than A3-mediated mutagenesis, but AZT resistance from the 
D67N mutation is more likely to occur from A3-mediated mutagenesis than RT.  
We also examined if exposure to A3F/A3G in a single round of replication could accelerate 
the development of viruses resistant to the Mixed ARV TLE regimen. We found that the No A3 
condition had more robust RT signal at day 15 than the A3F/A3G exposed virus which had 3.5-
fold less RT signal and did not become detectable until day 24 (Figure 2.4J). Proviral DNA and 
gRNA was isolated from each of these drug resistant virus populations and sequenced. For both 
the No A3 and A3F/A3G conditions, the same drug resistant mutations required for viral 
replication in the presence of the Mixed ARVs were found in the gRNA, which were K65R, 
M184I, K103S/N, and G190R/E. Although the codon mutation frequencies were higher in the 
proviral DNA for the No A3 condition, the virus from the No A3 and A3F/A3G conditions 
contained similar levels of mutations (Figure 2.4K-L).  
Although the A3s could contribute to drug resistant virus variants arising for 3TC and 
Mixed ARV treatments, the RT signal obtained was less than conditions with No A3 (Figure 2.4E, 
J). Even with AZT, the RT signal was at least 3-fold less than virus isolated in the absence of A3s 
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for the other single drug experiment with 3TC (Figure 2.4E, H). These data suggest that A3 
enzymes can contribute to drug resistance, but that there may be additional mutations occurring 
from A3-mediated mutagenesis that compromises the replication capacity of the virus.  
2.4.6 Drug resistant viruses derived from A3-mediated mutagenesis have less replication 
capacity 
To examine if there are consequences of A3-mediated mutagenesis on virus replication 
capacity we tested for emergence of drug resistant variants using the genetically related CEM-SS 
and CEM cells that have nearly undetectable expression and normal A3F and A3G expression, 
respectively230. We genotyped the A3F of the CEM cells and found that they have the commonly 
occurring heterozygous A3F genotype of 108S/231I and 108A/231V160,212. In treatment naïve 
cohorts, the A3F 108A/231V genotype has been associated with lower set-point viral load and 
slower rate of progression to AIDS that appeared to be due to partial resistance to Vif160. These 
CEM-SS/CEM cells were used to enable differentiation between A3- and RT- induced mutations 
while having continuous encapsidation of endogenously expressed A3s from CEM cells (Figure 
2.5A). Without any drug selection, the virus produced from CEM-SS and CEM cells both had peak 
RT activity after 24 to 27 days (Figure 2.5B). The peak RT activity from the CEM cells was 1.6-
fold less than from CEM-SS cells (Figure 2.5B). Sequencing of proviral DNA and cDNA isolated 
from gRNA showed that although there were more drug resistance mutations in the CEM-SS 
conditions, the types of mutations between the no A3 (CEM-SS) and A3 (CEM) conditions were 
similar types, suggesting they resulted from RT error (Figure 2.5C-D).  
To examine specifically the function of A3s in emergence of drug resistance, we grew 
CEM-SS and CEM cells in either 3TC or AZT. Data from infections in U87 CD4+ CXCR4+ cells 
suggested that the M184I mutation in replicating viruses was induced more efficiently by RT error 
than A3-mediated mutagenesis (Figure 2.4). In support of this line of reasoning, we isolated viruses 
that had high RT activity from CEM-SS cells in the presence of 150 μM 3TC (Figure 2.5E). 
Although we could isolate viruses from CEM cells at 150 μM 3TC, the level of RT activity was 
24-fold lower than viruses from CEM-SS cells (Figure 2.5E). The M184I was present in gRNA 
for both CEM-SS and CEM cells, but the frequency was 2.5-fold higher in virus from CEM-SS 
cells (Figure 2.5F-G). There were also multiple other drug resistance mutations present, such as 
K103S/N in CEM-SS cells, consistent with RT-induced mutations, and D67N in CEM cells, 
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consistent with A3-mediated mutagenesis (Figure 2.2C and Figure 2.5F-G). Interestingly, the 
G190R occurred at a high frequency in proviral DNA of viruses from CEM-SS cells, but not CEM 
cells, even though this codon has an A3 deamination motif and was a preferred deamination site 
for A3G in single-cycle infectivity assays (Figure 2.2F and Figure 2.5F-G).  
For selection of drug resistant variants in the presence of AZT, consistent with the results 
from U87 CD4+ CXCR4+ cells, the CEM cells resulted in AZT resistance at 25 μM AZT, but the 
CEM-SS cells resulted in resistance only at 6.25 μM AZT (Figure 2.4 H-I and Figure 2.5H, J). We 
also obtained virus from CEM cells resistant to 6.25 μM AZT, but the RT activity had ~40-fold 
less RT activity than drug resistant virus from CEM-SS cells (Figure 2.5H). Even the CEM derived 
drug resistant virus isolated at 25 μM AZT had 15-fold less RT activity than CEM-SS derived 
virus resistant to 6.25 μM AZT (Figure 2.5H, J). All the AZT resistance was from the D67N 
mutation in the gRNA, since we did not recover any T215F/Y resistance mutations in gRNA, 
although it was found in the proviral DNA of viruses isolated from both CEM-SS and CEM cells 
(Figure 2.5 I, K). These data collectively show that although A3s can induce drug resistance, the 
resulting viruses had less replication capacity than drug resistant viruses derived from RT-induced 
mutations alone. 
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Table 2.2 Emergence of 3TC or AZT resistant viruses in the absence or presence of 
encapsidated A3F/A3G. 
  
Experiment was carried out as detailed in Figure 2.4A 
sketch for 3TC and AZT. Occurrence of drug resistant 
viruses was scored for four independent experiments. 
No notation means that no drug resistant virus was 
isolated.  
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Figure 2.4 Exposure of WT HIV-1 to A3G and A3F for a single round of replication can 
generate drug resistant viruses. (A) U87 CD4+ CXCR4+ cells were cultured for 30 d in with no 
drug or in the presence of increasing amounts of 3TC (9.38-150 µM), AZT (6.25-50 µM), or Mixed 
ARVs. (B) Virus replication was measured using an RT assay and showed that the virus replication 
peaked in the U87 CD4+ CXCR4+ culture at day 6. (C-D) Drug resistance mutations were present 
in both provirus DNA and virus gRNA for the No A3 and coexpressed A3F and A3G (A3F/A3G) 
condition. (E) Virus resistant to 75 µM 3TC (No A3) and 18.7 µM 3TC (A3F/A3G) was isolated. 
(F-G) Virus resistant to 3TC had the corresponding drug resistance mutation at M184I in gRNA, 
along with drug resistance mutations for other ARVs. (G) The K65R mutation that provides 
additional resistance to 3TC was found in the A3F/A3G condition. (H) Virus resistant to 12.5 µM 
AZT was isolated from the A3F/A3G condition. (I) Virus resistant to AZT had the corresponding 
drug resistance mutations at D67N and T215F/Y, along with drug resistance mutations for other 
ARVs. (A-I) Data was obtained from the experiments listed in Table 2.2. Virus replication in the 
absence of drug was determined for each experiment in the No A3 and A3F/A3G condition, but 
only one representative curve is shown for each condition in panel B. (J) Virus resistant to a 1:32 
dilution of Mixed ARVs (TDF, 3TC, EFV) was isolated, but similar to the other drug resistant 
viruses, the amount of RT activity in the supernatant was less than without the Mixed ARV. (K-
L) Virus resistant to TDF, 3TC, and EFV had corresponding mutations in K65R, M184I, and 
K103S/N, respectively, along with drug resistance mutations for other ARVs.  
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Figure 2. 5 Drug resistant viruses induced by A3G- or A3F- mediated mutations have less 
replication capacity than drug resistant viruses that arise from RT-induced error. (A) CEM-
SS (permissive) or CEM cells (non-permissive) cells were cultured for 30 d in with no drug or in 
the presence of increasing amounts of 3TC (9.38-150 µM) or AZT (6.25-50 µM). (B) Virus 
replication was measured using an RT assay and showed that the virus replication peaked in the 
CEM-SS culture at day 27 and the CEM culture at day 24. (C-D) Drug resistance mutations were 
present in both provirus DNA and virus gRNA for the No A3 and coexpressed A3F and A3G 
(A3F/A3G) condition. (E) Virus resistant to 150 µM 3TC was isolated fro mboth CEM-SS and 
CEM cultures (F-G) Virus resistant to 3TC had the corresponding drug resistance mutation at 
M184I in gRNA, along with drug resistance mutations for other ARVs for (F) CEM-SS and (G) 
CEM cells. (H) Virus resistant to 6.25 µM AZT was isolated from cultures of CEM-SS and CEM 
cells. (I) Virus resistant to AZT from the CEM-SS culture was sequenced and had the 
corresponding drug resistance mutations at D67N and T215F/Y, along with drug resistance 
mutations for other ARVs. (J) Virus resistant to 25 µM AZT was isolated from CEM cell culture. 
(K) Virus resistant to AZT from the CEM culture was sequenced and had the corresponding drug 
resistance mutations at D67N and T215F/Y, along with drug resistance mutations for other ARVs. 
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2.5 Discussion 
The extent to which A3-mediated mutagenesis can contribute to the development of drug 
resistance is not clear. This could be due to different results from several studies using different 
experimental systems. In particular, some key limitations from previous studies were that only 
A3G instead of multiple A3s was assessed, the bias of RT to induce G→A mutations was not 
considered, only one antiviral drug was used, and only viral recombination with ΔVif HIV or HIV 
with partially inactive Vif was considered. To overcome these past limitations, we used WT HIV 
and assessed the contribution of A3F and A3G on drug resistance to multiple drugs, alone and in 
combination, in comparison to conditions with no A3 enzymes. We determined that all the G→A 
RT-induced mutations were in a G→A context that matched that of A3F or A3G, confounding the 
interpretation of many previous studies. Of utmost importance, we found that expression of both 
A3F and A3G in the HIV producer cells resulted in a protection of A3F from complete Vif-
mediated degradation and resulted in a proviral mutational load from approximately equal 
contributions of A3F and A3G, despite A3F previously being found less active in a ΔVif HIV 
infection133,217,218,233,234. Altogether, in separate cell lines we found the consistent result that 
although A3 enzymes could induce drug resistant mutations that resulted in viral replication under 
drug selection pressure, those viruses had less replication capacity than drug resistant viruses 
induced by RT alone. Thus, the contribution of A3-mediated mutations to the emergence of drug 
resistance is unlikely to be significant. These data support a model in which A3 enzymes cooperate 
to ensure viral suppression rather than viral evolution. 
Consistent with previous studies, we also found in our mutation analysis that A3G could 
induce the M184I mutation in proviral DNA150,216. We found in a single-cycle infectivity assay 
with WT HIV that A3G could induce this mutation in the absence of 3TC at a higher level than 
A3F and RT alone (Figure 2.2). However, despite this ability we found that A3G was less able to 
produce drug resistant virus that could replicate as robustly as drug resistant viruses that emerged 
in the absence of A3G and A3F (Figure 2.4 and Figure 2.5). Further, in the U87 CD4+ CXCR4+ 
cells, the virus isolated from day 6 had approximately equal levels of the M184I mutation between 
the No A3 and A3F/A3G condition, in contrast to the single-cycle infectivity assay, and suggesting 
that RT over several replication cycles can also induce the M184I mutation (Figure 2.2 and Figure 
2.3). Nonetheless, that we did isolate replication competent 3TC resistant virus in the presence of 
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A3F and A3G underscores that viral inactivation after A3-mediated mutagenesis during a WT HIV 
infection is not guaranteed (Figure 2.4 and Figure 2.5). There are several missense mutations that 
can be induced by A3 enzymes that do not inactivate key enzymes such as protease77,133,134. 
However, we observed that sublethally mutated and drug resistant proviral genomes are unlikely 
to replicate as well as WT HIV. As a result, the differentiation between sublethal mutagenesis and 
viral suppression appears to be the number of mutations, in addition to the nature of the mutations. 
A3G has been shown to be very efficient at inactivation of ΔVif HIV with some reports suggesting 
that even a single encapsidated A3G molecule can induce lethal mutations that inactivate the 
virus131,133,217,218,233-236. Even though A3G is more efficient at inducing mutations than A3F in a 
ΔVif HIV infection, the A3G is also more sensitive to Vif (Figure 2.1). In our study, A3G was 
always co-expressed with A3F. This may have resulted in additional mutations that led to drug 
resistant viruses with less replication capacity126,144,237-239. 
Although A3F has been implicated more than A3G for inducing genetic diversity, no 
studies have directly tested the ability of A3F to promote HIV drug resistance133,217,219. Here we 
showed that A3F can preferentially induce the D67N mutation that results in AZT resistance and 
this occurred in the presence of Vif (Figure 2.3, Figure 2.4, Figure 2.5). In U87 CD4+ CXCR4+ 
cells with virus exposed to A3F/A3G for only one round of replication, the A3F/A3G condition 
resulted in AZT resistant virus with more replication capacity than the No A3 condition for two of 
the four experimental replicates (Table 2.2, Figure 2.3). Despite this induced resistance, we also 
found that in CEM cells where there is continual encapsidation of A3F and A3G, the resulting 
viruses still became resistant to AZT, but had less replication capacity than the AZT resistant 
viruses that emerged from CEM-SS cells in the absence of any A3s (Figure 2.5). Our data 
demonstrated that the coordinate expression of A3G with A3F results in more encapsidation of 
A3F due to protection from Vif-mediated degradation, resulting in almost equal contribution of 
mutations from A3F and A3G in a WT HIV infection (Figure 2.1, Figure 2.2). This suggests that 
the combination of GG→AG and GA→AA mutations could have a higher inactivation potential 
than each alone in a WT HIV infection236,237. This may be due to differences in enzyme 
processivity that result in A3F inducing more mutations that are widely spaced, potentially at least 
partially inactivating more target proteins, and A3G inducing clusters of mutations that have high 
inactivation potential if they fall within conserved regions or enzyme active sites133.  
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Our study also addressed the contribution of RT-induced G→A mutations and whether the 
number of A3-induced mutations could exceed the RT error rate in a single round of replication. 
Several studies have assessed levels of A3-induced mutagenesis using proviruses recovered after 
unknown numbers of multiple rounds of virus replication and sometimes from infections with 
naturally occurring defective Vif viruses119,150,152,172,239. If the proviral DNA is “hypermutated”, 
then recombination with a WT or sublethally mutated virus would be required to recover drug 
resistant mutations. While this may efficiently occur in cell culture, it appears less likely in a 
clinical infection, suggesting that this is not a main route of A3-induced drug resistance, if it 
occurs150,152. Rather, the sublethal mutagenesis that would occur in the first round of replication 
would be the most likely mechanism for A3 enzymes to contribute to drug resistance. In this 
situation, we found evidence of potential sublethal mutagenesis since A3-induced mutations 
decreased from ~20-fold above RT error to only 4-fold above RT error (Figure 2.2). These 
mutations did not cause any decrease in viral replication in the absence of drug selection (Figure 
2.1). However, in the presence of drug selection where only select viruses could replicate, the 
effect of the A3-induced mutations was visible because the virus replication, as measured by an 
RT assay, consistently resulted in less signal in the presence of AZT, 3TC, and the combined 
ARVs (Figure 2.4 and Figure 2.5). Importantly, in a spreading infection we found that the chance 
for RT to induce the M184I mutation in comparison to viruses exposed to A3G and A3F for a 
single round of replication was equal, but under drug selection pressure, the no A3 condition 
produced a much stronger pool of 3TC resistant virus (Figure 2.4 and Figure 2.5). These data 
suggest that previous studies have underestimated the ability of RT alone to induce this mutation. 
Particularly since all of our quantified RT induced G→A mutations were within a relevant A3 
mutation context (Figure 2.2), consistent with analysis of the mutational bias of HIV-1 in proviral 
DNA from HIV+ individuals226 and studies characterizing RT fidelity90,148,229. Only the resistance 
to AZT was consistently induced by A3 enzymes, likely A3F, but AZT resistant viruses 
continually exposed to A3G and A3F had lower replication capacity than viruses not exposed to 
A3G and A3F (Figure 2.5). With a combined ARV treatment, the single round of exposure to A3s 
enabled resistance, but it was less robust than RT alone (Figure 2.4). Altogether, the data suggest 
that the impact of A3F and A3G on drug resistance is less than RT alone.  
Previously published studies found different results than ours and suggest that A3G alone 
can induce the M184I mutation required for virus resistance to 3TC. In Mulder et al., a previously 
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identified HIV-1 with point mutations in Vif that caused less A3G degradation was used to 
generate a pool of proviruses150. These proviruses, similar to the ones isolated in our study, 
contained the M184I mutation prior to any drug exposure (Figure 2.2)150. Also similar to our results 
in using ΔVif HIV, the A3G was able to induce the M184I mutation to a much greater extent than 
A3F and RT (Figure 2.2)150. However, in the Mulder et al. study, the large majority of provirus 
was inactive and in order to select for resistant viruses, the provirus had to be co-infected with WT 
HIV150. With no WT virus added to the cells for recombination as in the Mulder et al. study, we 
found that A3G was not inducing 3TC drug resistance (Figure 2.4)150. In the U87 CD4+ CXCR4+ 
cells, we found that although the frequency of the M184I mutation was similar between the No A3 
and A3F/A3G conditions in the absence of 3TC, in the presence of 3TC the No A3 condition had 
300- and 600- fold higher frequencies of the M184I mutation in provirus and virus, respectively 
(Figure 2.4). While the scenario proposed by Mulder et al., where individuals have viruses with 
partially defective Vifs does occur, the extent to which superinfection with WT HIV and 
recombination with defective viruses occurs appears to decrease the possibility of A3G-induced 
drug resistance arising by this mechanism120,152,159. In contrast, a study by Kim et al. used an 
experimental system similar to ours with WT HIV and CEM-SS cells, but obtained results 
indicating that only CEM-SS cells that stably expressed A3G, but not CEM-SS cells alone, could 
induce 3TC drug resistance216. Although we did recover 3TC resistant virus from CEM cells, it 
replication ability was 24-fold lower than CEM-SS cells (Figure 2.5). The key difference between 
our studies is that we also had A3F present, which may result in higher levels of mutagenesis and 
ensure viral inactivation. In contrast, Kim et al. found no effect of A3G on viral fitness, in 
agreement with an early work from Sadler et al.216,240 While this is in agreement with our data 
showing equal virus replication in the presence and absence of A3G and A3F without drug 
selection, it appears that the drug resistant viruses that become selected from the viral population 
have additionally acquired collateral mutations that impair virus replication (Figure 2.4 and Figure 
2.5).  
Despite different results from some cell-based experiments, our data are in agreement with 
several clinical and in silico studies regarding the effects of collateral A3-induced mutations. An 
early study by Jern et al. found similar results through in silico simulation analysis that concluded 
A3G deaminations have been a factor in HIV evolution, but only a small proportion of the 
deaminations could be responsible for drug resistance mutations, indicating that there is not always 
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a direct connection between resistance and A3-mediated mutagenesis172. This was supported by a 
study by Delvis-Frankenberry et al. that suggested hypermutated proviruses occur, but are rarely 
rescued by recombination and that sublethal mutagenesis for A3G and A3F is negligible since it 
occurs at a rate less than the RT mutations152. While our single-cycle infectivity assays found a 
larger number of mutations due to A3G and A3F in the presence of Vif (Figure 2.2), the overall 
conclusions were the same; that the effect of A3-mediated mutagenesis appeared to be either be 
very low and insignificant or high enough to inactivate or partially suppress viral replication152. In 
particular, several studies have found stop codons almost concomitant with A3-mediated 
mutagenesis, even with WT HIV infections and in clinical studies152,224,227,228. In particular, the 
M184I mutation causes RT to be less processive, although this can be compensated for with an 
E138K mutation241-246. Nonetheless, the M184I mutation slows the synthesis of DNA and enables 
more time for A3-mediated mutagenesis, resulting in more mutations and making viral inactivation 
more likely and the contribution of A3 enzymes to drug resistance less likely225. The level of A3-
induced mutations differs for various anatomical compartments, but consistently A3 mutated 
proviral genomes also contain a high proportion of inactivating mutations159. Further, during a WT 
HIV infection, even the E138K mutation is more likely to be induced by RT, due to its G→A error 
bias226, consistent with our sequencing data (Figure 2.2). Altogether, the data suggest that there is 
a higher likelihood for RT to induce drug resistant viruses with high replication capacity, rather 
than A3 enzymes. Collectively the data from our study and others suggests that there is a large 
dependence on the environmental selection pressures for whether A3-induced mutations result in 
replication competent drug resistant virus. This also appears to be the case for the involvement of 
A3 enzymes in the CTL response. Where some studies have found that A3-induced mutations can 
increase CTL recognition of HIV infected cells others have found that A3-induced mutations 
predominantly decrease the recognition of HIV infected cells173,174,214,215,220-222. Either way, it has 
also been found that A3-induced mutations usually coincide with functional viral inactivation, but 
not disruption of transcription173,214. Altogether, the effect of A3 enzymes can bias the immune 
response to target cells carrying defective proviruses, rather than causing direct immune escape 
per se214. This broader view suggests that what is more important than whether the CTL response 
is evaded or accentuated is whether the provirus is actively able to replicate or not. When this 
broader view is applied to A3-induced drug resistance, the data from our work and others suggest 
that although A3 enzymes can induce drug resistance in proviral DNA, the chance of these viruses 
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being replication competent and having a competitively strong replication ability is less likely than 
mutations induced by RT alone. 
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Primers used for amplifying cDNA and the specific regions on pol harbouring the potential 
drug resistance mutations 
Ext F p7.9 AAAGCATTGGGACCAGGAGCGACACTAGAAGARATGATGACAGCAT
GYCA 
Half RT TATTTCTGCTATTAAGTCTTTTGATGGGTCA 
Ext F 
p7.10 
GGAGCGACACTAGAAGAAATGATGACAGCATGYCARGGAGTRGGRG
GRCY 
Half Pol TCTGCCAGTTCTAGCTCTGCTT 
D67N_F CCAGTAAAATTAAAGCCAGGAATG 
D67N_R AGTATACTTCCTGAAGTCTTCATCT 
E138K_F AATAAGAGAACTCAAGACTTCTGG 
E138K_R TGTTCTATGCTGCCCTATTTCTA 
M184I_F CATACCTAGTATAAACAATGAGACAC 
M184I_R CTGTCTTTTTCTGGCAGCACTAT 
D67N_F_
MS 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAGTAAAATTAA
AGCCAGGAATG 
D67N_R_
MS 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGTATACTTCCTG
AAGTCTTCATCT 
E138K_F_
MS 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAATAAGAGAACTC
AAGACTTCTGG 
E138K_R_
MS 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGTTCTATGCTGC
CCTATTTCTA 
M184I_F_
MS 
TCGTCGGCAGAGTCAGATGTGTATAAGAGACAGCATACCTAGTATA
AACAATGAGACAC 
M184I_R_
MS 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGTCTTTTTCTG
GCAGCACTAT 
Table 2.3 List of primers 
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3.1 Abstract  
The APOBEC3 enzyme family are host restriction factors that induce mutagenesis of HIV proviral 
genomes through the deamination of cytosine to form uracil in nascent single-stranded (-)DNA. 
HIV suppresses APOBEC3 activity through the HIV protein Vif, that induces APOBEC3 
degradation. Here we compared two common polymorphisms of APOBEC3F. We found that 
although both polymorphisms have HIV-1 restriction activity, APOBEC3F 108A/231V can 
restrict HIV-1 ΔVif up to 4-fold more than APOBEC3F 108S/231I and is partially protected from 
Vif-mediated degradation. This resulted from higher levels of steady state expression of 
APOBEC3F 108A/231V. Individuals are commonly heterozygous for the APOBEC3F 
polymorphisms and these polymorphisms formed in cells, independent of RNA, hetero-oligomers 
between each other and with APOBEC3G. Hetero-oligomerization with APOBEC3F 108A/231V 
resulted in partial stabilization of APOBEC3F 108S/231I and APOBEC3G in the presence of Vif. 
These data demonstrate functional outcomes of APOBEC3 polymorphisms and hetero-
oligomerization that affect HIV restriction. 
3.2 Importance  
APOBEC3 enzymes are a barrier to HIV infection and suppress HIV replication by inducing 
mutagenesis of HIV proviral DNA. To counteract this host restriction system HIV uses Vif to 
induce degradation of relevant APOBEC3 enzymes. Although there is a constant battle between 
host and virus for suppression of replication and a counteraction, the HIV mutation rate far exceeds 
that of humans and facilitates a faster rate of adaptation. As a result, protective measures such as 
having multiple host genotypes can guard populations by slowing the rate of viral adaptation. We 
examined if two common genotypes of APOBEC3F were an example of multiple genotypes that 
can help protect the host. We found that the two common APOBEC3F genotypes most often occur 
as heterozygous alleles and that the one allele that was more protective could stabilize APOBEC3F 
and APOBEC3G in cells to increase virus encapsidation and partially protect against Vif mediated 
degradation.     
3.3 Introduction 
 APOBEC3 (A3) enzymes are a family of deoxycytidine deaminases that can act as host 
restriction factors for HIV 17,92. The A3 enzymes deaminate cytosine in single-stranded (ss) DNA 
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to form uracil 25,247-249. Of the seven human A3 enzymes, there are five that can restrict the 
replication of HIV in CD4+ T cells through the formation of uracils in (-) strand proviral DNA. 
These enzymes, A3D, A3F, A3G, A3H (haplotypes II, V, and VII), and A3C (S188I) restrict HIV 
with varying efficiencies 23,110,111,126,131,209,250,251. In an HIV infected CD4+ T cell, these enzymes 
can become encapsidated into assembling virions through an interaction with cellular or HIV 
genomic RNA that is also bound to HIV Gag 117,183. After virion maturation and infection of a 
target cell, the encapsidated A3 enzymes can access single-stranded HIV (-) DNA when it is 
synthesized and exposed through reverse transcription and RNase H activity 125. The cytosines that 
become deaminated to uracil are copied by the reverse transcriptase during (+) DNA synthesis and 
result in guanine to adenine (G→A) mutations on the coding strand 25,125,247-249. These mutations 
can induce DNA repair enzyme-mediated degradation of proviral DNA or result in functional 
inactivation of integrated proviral DNA 205. HIV-1 Vif suppresses the encapsidation and activity 
of A3 enzymes by mediating their polyubiquitination and proteasomal degradation 26,29-32,252,253. 
HIV-1 Vif hijacks a Cullin 5 E3 ubiquitin ligase complex and acts as the substrate receptor by 
replacing the host protein SOCS2 29. This enables HIV-1 Vif to interact directly with components 
of the ubiquitin ligase complex, Elongin C and Cullin 5 33. HIV-1 Vif can also directly interact 
with A3D, A3F, A3G, A3H, and A3C, which induces their ubiquitination and proteasomal 
degradation 185,254-256. Obligatory for stability, Vif also interacts with the transcription cofactor 
CBF-β 27,257. 
 Despite the presence of Vif, A3 enzymes are still able to be encapsidated into HIV virions 
and induce mutagenesis 156,195-204,258. Although translation of Vif mRNA results in high levels of 
Vif in cells before virus particle assembly, which depletes A3s from infected CD4+ T cells, the 
induced degradation of A3s is not complete 259. Evidence of this comes from high levels of A3 
induced stop codons and missense mutations in HIV proviral DNA in acute and chronic proviral 
DNA isolated from HIV+ individuals 199. Sequencing of integrated proviral genomes from multiple 
studies have revealed that the mutations are present on the (+) DNA in both a 5′GG→5′AG context 
and a 5′GA→5′AA context 127,156,195-204,258.Mutations in the  5′GG context originates primarily 
from A3G that deaminates preferentially in 5′CCA motifs on the (-) DNA (underlined C 
deaminated) 125. This sequence context most often results in mutations that introduce stop codons 
and mutations at glycines 77.  Mutations in the 5′GA context originates primarily from A3D, A3F, 
A3H, and A3C (S188I) due to a preference to deaminate in 5′TC motifs on the (-) DNA 
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126,127,137,260. Mutations at the 5′TC motif can also introduce stop codons and missense mutations 
in a wider variety of amino acids 77. The fate of these mutations may inactivate HIV-1 or may lead 
to evolution in various forms, such as drug resistance, CTL escape, and changes in co-receptor 
usage 150,171,174,215,219,261. However, depending on the experimental system some studies have found 
that A3 enzymes do not contribute to drug resistance and may enhance CTL recognition 
152,172,221,222,261. Although A3G is the most active deaminase in a ΔVif HIV-1 infection, it is also 
very sensitive to Vif 133,218,262. Thus, despite there being lower activity from A3D and A3F in ΔVif 
HIV-1 infections, there is some evidence that A3F is less sensitive to Vif, and as a result, may be 
a greater contributor to mutagenesis during HIV infections in vivo 131,133,136,160,217. There is also 
evidence that in chronically infected individuals that HIV-1 Vif can acquire mutations that result 
in partial activity, thereby enabling A3 encapsidation and mutagenesis 119. However, it is unlikely 
that these mutations in Vif are acquired early in infection and since A3-mediated mutagenesis is 
found in acute infections, the data suggest that other mechanisms can enable A3 encapsidation in 
the presence of Vif 199. 
 Resistance to Vif mediated degradation has been characterized for some A3 enzymes. A3H 
exists as seven major haplotypes in humans with different protein stability, HIV restriction ability, 
and sensitivity to Vif 111,113,263. These haplotypes result from a combination of five different single-
nucleotide polymorphisms (SNPs) 111,113,263. The diversity of A3H in the human population 
necessitates constant adaptation of HIV-1 Vif to A3H, especially since stable and restrictive A3H 
haplotypes (II, V, and VII) show population stratifications 111,113,127. These dynamics result in a 
situation where A3H can act as a transmission barrier for some HIV-1 strains that do not have a 
Vif capable of inducing A3H degradation 264. At the very least, this A3H resistance to some HIV-
1 Vifs can increase the time until CD4+ T cell counts decrease or until the development of AIDS, 
while Vif acquires the adaptive mutations to overcome A3H 127. The number of SNPs in other A3s 
is significantly lower and most commonly they have been found to result in inactivation of the A3 
or no effect 210-212. Exceptions are A3D and A3C in which SNPs have resulted in increased activity 
110,209,212. Interestingly, despite cell based assays not uncovering differences in a common variant 
of A3F A108S/V231I, a population based analysis of multiple pre-treatment cohorts of HIV+ 
individuals showed that the A3F 231V variant was associated with lower viral load and slower 
rate of progression to AIDS 160,212,233. The authors suggested that the 231V polymorphism might 
increase resistance to Vif 160. Despite this amino acid not being within the canonical Vif binding 
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interface on A3F, this observation was also previously reported for A3F 108A/231V 
126,186,190,265,266.  
 Here we assessed the A3F 108S/231I and A3F 108A/231V variants for their ability to 
restrict HIV-1 replication in the presence and absence of Vif. Based on past evidence that A3F can 
interact with itself and A3G, in an RNA-independent manner 144, we assessed how each A3F 
variant restricted HIV-1 replication when expressed together and in the presence of A3G. Notably, 
the SNPs responsible for the A3F 108A/231V and 108S/231I (rs202390, rs2076101) have been 
identified to commonly occur together in genetic studies 212,233. Further, analysis of multiple human 
populations from the Ensembl genome browser (release 94) showed that these SNPs are in high 
linkage disequilibrium (r2 > 0.95) for European, South Asian, and East Asian populations and 
linkage disequilibrium also occurs, but at lower frequencies, for Mixed American (r2 > 0.87) and 
African (r2 > 0.35) populations 267. As a result, we refer to these variants as A3F 231V or A3F 
231I for brevity and because this specific variation was correlated epidemiologically in affecting 
HIV-1 progression 160,212,233. Our analysis of these A3F variants found that the A3F 231V is a more 
efficient restriction factor for HIV-1 than A3F 231I. The increased restriction was due to an 
increase in A3F steady state levels in cells. This increased steady state level of A3F 231V resulted 
in a partial protection from Vif-mediated degradation. Notably, population analysis demonstrated 
that the A3F 231V and A3F 231I alleles occurred most often together, rather than the homozygous 
alleles. This appeared to have a functional benefit since the interaction of A3F 231V could also 
increase the Vif resistance of A3F 231I and A3G, providing a possible reasoning for how high 
numbers of A3 induced mutations may be acquired in HIV+ individuals.  
3.4 Results 
3.4.1 A3F 231V more efficiently restricts HIV-1 infection than A3F 231I 
The A3F 231V allele has been shown to be advantageous in HIV+ individuals, but the 
reason for this was not fully explored 160. Here we conducted an assessment of the HIV-1 
restriction ability of A3F 231V and A3F 231I. The effect of untagged A3F 231V and A3F 231I on 
VSV-G pseudotyped ΔVif HIV-1 infectivity was assessed using transient transfection of different 
amounts of A3F vector in single-cycle replication assays. Over a range of A3F plasmid transfection 
amounts, the A3F 231V restricted ΔVif HIV-1 1.4-fold (25 ng, p≤0.05), 1.6-fold (50 ng, p≤0.01), 
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and 4.0-fold (100 ng, p≤0.001) more than A3F 231I (Figure 3.1A). Overall the ability for A3F to 
restrict ΔVif HIV-1 was still 1.5-fold (25 ng, p≤0.01), 1.8-fold (50 ng, p≤0.01), and 13.6-fold (100 
ng, p≤0.001) less than A3G, for the more active A3F 231V variant, consistent with previous reports 
(Figure 3.1A) 131. Also consistent with A3F 231V being protective in HIV+ individuals 160, the 
A3F 231V enabled modest restriction of virus replication in the presence of Vif, which was not 
observed for A3F 231I or A3G (Figure 3.1B, p≤0.01 for 50 ng and 100 ng).  
 To confirm that decreases in infectivity in the presence and absence of Vif correlated with 
virion encapsidation of the A3 enzymes, the cell lysates and virions from the replication assays 
were analyzed after proteins were resolved by SDS-PAGE and transferred to membranes for 
immunoblotting. The native antibody used to detect A3F was only able to detect cellular 
expression (Figure 3.1C-E) and not virion encapsidation, except at the 100 ng transfection amount 
(Figure 3.1E and data not shown). These blots showed that the A3F 231V had a higher steady state 
expression level than A3F 231I in the absence of Vif (5- to 10- fold) and presence of Vif (2.5- to 
15- fold) (Figure 3.1C-E), consistent with higher decreases in HIV-1 infectivity in both of these 
conditions (Figure 3.1A-B). At the highest plasmid transfection amount (100 ng), the A3F variants 
could be detected in the virus particles. The A3F 231V was encapsidated 5-fold more than A3F 
231I in the absence of Vif and in the presence of Vif encapsidation of the A3F 231V, but not the 
A3F 231I was detected (Figure 3.1E). Collectively, these data suggest that the A3F 231V is 
partially protected from Vif-mediated degradation. Similar limitations with a native antibody for 
A3G were identified in that the cellular expression levels were detected with the native antibody, 
but the encapsidation was not detected until the plasmid transfection amount reached 100 ng, 
despite evidence of HIV-1 restriction in the single-cycle replication assays (Figure 3.1A and F-H). 
Although significant amounts of A3G were detected in the virus in the presence of Vif at the higher 
transfection amount (Figure 3.1H), there was no observable decrease in infectivity (Figure 3.1B), 
presumably due to Vif-mediated inhibition of A3G catalytic activity and processivity that has been 
previously characterized 193,194. 
 To investigate further if the A3F 231V was partially resistant to Vif-mediated degradation 
we used V5-tagged A3F 231V and A3F 231I constructs. The tags were used to avoid any possible 
recognition differences by the native antibody, which recognizes unknown epitopes in the C-
terminal half, and to facilitate quantification of immunoblots at lower plasmid transfection 
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amounts. We repeated the experiment in Figure 3.1D using 50 ng of V5-tagged A3F expression 
plasmids in the presence or absence of Vif during a single-cycle replication experiment. The V5-
tagged A3F-231V had the same features as the untagged enzyme and was expressed 5-fold more 
than the V5-tagged A3F-231I and was partially resistant to Vif-mediated degradation, in contrast 
to V5-tagged A3F-231I (Figure 3.2A). The higher steady state levels of the A3F 231V also resulted 
in higher levels of virion encapsidation in comparison to the A3F 231I, in the presence and absence 
of Vif (Figure 3.2A). Having established that the higher steady state levels of A3F 231V were 
indeed due to protein levels in cells and not differences in antibody recognition, we used the V5-
tagged constructs to address the basis for the A3F 231V partial protection from Vif-mediated 
degradation. We transfected different plasmid amounts of the V5-tagged A3F variants that resulted 
in approximately equal steady state cellular expression. Using 10 ng of A3F 231V-V5 plasmid and 
50 ng of A3F 231I-V5 plasmid, we cotransfected increasing amounts of Vif from an expression 
vector. Quantification of the immunoblot demonstrated that at these transfection amounts, in the 
absence of Vif, the steady state levels of both A3F 231V-V5 and A3F 231I-V5 were similar (Figure 
3.2B). With increasing amounts of transfected Vif, the induced degradation of both A3F variants 
were also similar (Figure 3.2B-C). Thus, the partial protection from Vif observed in Figure 3.2A 
and Figure 3.1C-E was not due to an inherent biochemical property of the A3F 231V, but rather 
the data suggest that the partial protection from Vif-mediated degradation was due to a higher 
steady state level of A3F 231V that exceeded Vif degradation capacity. Consistent with this line 
of reasoning, we observed stability differences between A3F 231V-V5 and A3F 231I-V5 after 
cyclohexamide treatment of transfected cells (50 ng plasmid transfected for each A3F variant). 
The A3F 231V steady state protein levels decreased 2-fold 10 h after cycloheximide treatment. In 
contrast, the A3F 231I steady state protein levels decreased 2-fold within 2 h after cycloheximide 
treatment and continued to decrease through the time course with an ultimate 4-fold decrease in 
protein level (figure 3.2D-E).   
  
83 
 
 
84 
 
 
Figure 3.1 A3F 231V and A3F 231I have different HIV-1 restriction abilities. infectivity was 
measured by β-galactosidase activity in reporter cells infected with HIV-1 ΔVif that was produced 
in the absence or presence of untagged A3G, A3F 231V or A3F 231I. Results were normalized to 
the no A3 condition. (B) HIV-1 +Vif infectivity was measured by β-galactosidase activity in 
reporter cells infected with HIV +Vif that was produced in the absence or presence of untagged 
A3G, A3F231V or A3F231I. Results were normalized to the no A3 condition. (A-B) Error bars 
represent the standard deviations of the mean calculated from three independent experiments. (C-
H) Immunoblotting with A3F native antibody was used to detect (C) 25 ng (D) 50 ng and (E) 100 
ng transfected A3F expressed in (C-E) cells and (E) encapsidated into HIV-1 virions in -Vif and 
+Vif conditions. Immunoblotting with A3G native antibody was used to detect (F) 25 ng (G) 50 
ng and (H) 100 ng transfected A3G expressed in (F-H) cells and (H) encapsidated into HIV-1 
virions in -Vif and +Vif conditions. The cell lysate and virion loading controls were α-tubulin and 
p24, respectively. (C-H) One representative blot from three independent experiments is shown. 
The A3 expression levels shown below the blots were calculated by setting a –Vif condition to 1.0 
and determining the relative values of other lanes. Immunoblots were conducted from three 
independent experiments and a representative blot is shown. 
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Figure 3.2 A3F 231V is expressed at higher steady state levels in cells. (A) Immunoblotting 
with V5 antibody after 50 ng of expression plasmid was transfected into 293T cells in the presence 
of HIV-1 to detect A3F 231V-V5 and A3F 231I-V5 in cells and encapsidated into HIV-1 virions 
in -Vif and +Vif conditions. (B) A3F 231V-V5 and A3F 231I-V5 plasmids were transfected into 
293T cells with amounts that resulted in equal steady state expression levels. Increasing amounts 
of Vif were cotransfected. The amount of Vif-mediated degradation was detected by analysing the 
intensity of the bands detected with antibody to the V5 tag. One representative blot from three 
independent experiments is shown.  (C) Quantified intensities of the bands from immunoblotting 
are shown. Error bars represent the standard deviations of the mean calculated from three 
independent experiments. (D) Immunoblotting with V5 antibody after 50 ng of expression plasmid 
was transfected into 293T cells to detect A3F 231V-V5 and A3F 231I-V5 after cycloheximide 
treatment. (E) Quantification of the protein levels after cycloheximide treatment showed 
differences in the stability of A3F 231V-V5 and A3F 231I-V5. Immunoblots were conducted from 
three independent experiments and a representative blot is shown. 
  
87 
 
3.4.2 A3F 231V induces more mutations than A3F 231I in HIV-1 proviral DNA  
We PCR amplified a 351 bp region of HIV-1 protease for sequencing under the conditions shown 
in Figure 3.1A (untagged A3s, 50 ng transfection amount) to determine the G→A mutations 
induced by A3F 231V and A3F 231I. We observed that in the absence of Vif that G→A mutations 
per kb were 2.46 for A3F 231V and 1.42 for A3F 231I (Table 3.1). The mutations were primarily 
in the A3F mutation context (Table 3.1, GA→AA). This ~2-fold difference in mutations is 
consistent with the decrease in infectivity (Figure 3.1A, 50 ng). However, both A3F variants were 
still less able to induce mutations than A3G (Table 3.1, 13.49 G→A mutations/kb). This at least 
5-fold difference in A3F and A3G induced mutations was consistent with previous data and has 
been found to be due to differences in enzyme processivity 133. As a result, these data emphasize 
the importance of the inherent biochemical characteristics in restriction capacity between A3s. 
However, when comparing A3F variants, the level of encapsidation appeared to be a determining 
factor that could increase A3F restriction efficiency for HIV-1 (Table 3.1, Figure 3.1E and Figure 
3.2A). 
 Importantly in the presence of Vif, the number of A3-induced mutations by A3F 231V and 
A3G were less disparate. A3G did not show significant restriction in the presence of Vif and 
accordingly induced 36-fold less mutations than in the absence of Vif (Table 3.1, 0.37 G→A 
mutations/kb). Consistent with the ability to partially avoid Vif-mediated degradation, the A3F 
231V only had a 4.8-fold decrease in induced mutations (Table 3.1, 0.51 G→A mutations/kb). 
Thus, in the presence of Vif the A3F 231V induced mutations were 1.4-fold more than A3G (Table 
3.1). In the presence of Vif, the A3F 231I induced mutations decreased 11-fold to 0.13 G→A 
mutations/kb, resulting in 2.3-fold less mutations than A3G and 4-fold less mutations than A3F 
231V (Table 3.1).  
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3.4.3 A3F genotypes are commonly heterozygous  
Since the A3F genotypes showed different abilities to restrict HIV and different steady state 
expression levels, we were interested to determine how often in the human population these 
different variant alleles were heterozygous or homozygous. This was of interest since we have 
previously shown that A3G and A3F can hetero-oligomerize in the absence of RNA 144. If the A3F 
variants were expressed in the same cell and hetero-oligomerized, the A3F expression levels and 
restriction ability could potentially be altered.  
 We obtained genotype data for the corresponding SNP (rs2076101) that results in the 
231V/I polymorphism from Ensembl (release 94) 267. The cumulative allele data from people of 
African, Mixed American, East Asian, European and South Asian populations showed that there 
was an equal frequency of the GTC (G) allele that resulted in the 231V polymorphism and ATC 
(A) allele that resulted in the 231I polymorphism (Table 3.2). Per population, the allelic 
frequencies varied, with only the European (EUR) population having an approximately equal 
frequency of the G and A alleles (Table 3.2). The Mixed American (AMR) and South Asian (SAS) 
were similar having approximately a 0.40 frequency of the G allele (Table 3.2). The African (AFR) 
and East Asian (EAS) populations were biased for one allele, with AFR populations having a 0.81 
frequency of the G and EAS having a 0.71 frequency of the A (Table 3.2). Despite these differences 
in allelic frequencies, there were high frequencies across all populations of the heterozygous 
genotype (A/G). The average frequency across all populations for the heterozygous genotype was 
0.42 and was similar to the individual genotype frequencies of the EUR, AMR, EAS, and SAS 
populations (Table 3.2). Even the AFR population with the lowest allele frequency of the G (0.04), 
had an A/G genotype frequency of 0.30 (Table 3.2). These data demonstrate that for many 
populations, the heterozygotic genotype is dominant. The exceptions are the AFR population 
where the homozygous G/G genotype is dominant (0.66) and the EAS population where the A/A 
genotype is dominant (0.50) (Table 3.2).   
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A 351 bp region of HIV-1 protease was PCR amplified from the three independent single-cycle 
replication experiments shown in Figure 3.1. Clones were sequenced, aligned with Clustal 
Omega268, and analyzed using Hypermut269. 
  
Table 3.1 Analysis of A3-induced mutagenesis in HIV-1 proviral DNA. 
Virus 
Condition 
A3 
enzyme 
Base pairs 
sequenced 
G→A 
mutations 
(total) 
GG→AG 
mutations 
(total) 
GA→AA 
mutations 
(total) 
G→A 
mutations 
(per kb) 
GG→AG 
mutations 
(per kb) 
GA→AA 
mutations 
(per kb) 
-Vif No A3 7722 2 0 0 0.26 0 0 
 A3F 231V 7722 19 2 14 2.46 0.26 1.81 
 A3F 231I 7020 10 2 6 1.42 0.28 0.85 
 A3G 6669 90 83 5 13.4 12.45 0.75 
+Vif No A3 15795 3 0 1 0.19 0 0.06 
 A3F 231V 15795 8 0 5 0.51 0 0.32 
 A3F 231I 15093 2 0 2 0.13 0 0.13 
 A3G 16142 6 4 1 0.37 0.24 0.06 
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3.4.4 A3F 231V and A3F 231I hetero-oligomerize with each other and A3G 
Based on these results showing that different A3F variants can be coexpressed within an 
individual, we determined whether the A3F variants could hetero-oligomerize with each other or 
A3G. A3F has been shown to form homo-oligomers and to hetero-oligomerize with A3G, in the 
absence of RNA 144. To determine oligomerization, we used a cotransfection scheme where one 
A3 had an HA-tag and the other A3 had a V5-tag and determined if one A3 could co-
immunoprecipitate the other A3. To ensure uniform co-expression of A3s on a per cell basis we 
used the pVIVO2 plasmid that has two transcription units within a single vector (see Materials and 
Methods) 144. We used the V5-tagged A3 to immunoprecipitate the binding partner, in the presence 
of RNase A, and found through blotting for HA that A3G-HA can interact with A3F 231I-V5, as 
shown previously (Figure 3.3) 144. We also determined that A3G-HA can interact with A3F 231V-
V5 and that A3F 231V-HA can interact with A3F 231I-V5 (Figure 3.3). 
3.4.5 A3F 231V promotes steay state levels of A3F321I and A3G 
Using the same pVIVO2 expression vectors that were used in the co-immunoprecipitations 
we conducted single-cycle replication assays to assess if combined expression changed the HIV-1 
restriction capability of the coexpressing A3s compared to the individual enzymes. To facilitate 
immunblotting of the samples resulting from the infectivity assays, we transfected tagged versions 
of the A3 enzymes (50 ng) using a combination of HA- and V5- tags so that each A3 was 
discernable by immunoblotting. The A3G was always HA-tagged, A3F 231I was always V5-
tagged and the A3F 231V was HA- or V5- tagged depended on whether it was coexpressed with 
A3G or A3F. In the absence of Vif, the A3G-HA alone and A3G-HA/A3F 231V-V5 decreased the 
infectivity similarly (Figure 3.4A). The A3G-HA/A3F 231I-V5 coexpression also decreased HIV 
infectivity, but the restriction was 3-fold less than the A3G-HA/A3F 231V-V5 restriction, although 
this was not a statistically significant difference (Figure 3.4A). However, both A3F 231I-V5 and 
A3F 231V-V5 alone restricted the replication of HIV ΔVif 3-fold (p≤0.001) and 6-fold less 
(p≤0.001), respectively, than when in combination with A3G (Figure 3.4A). These data extend 
previous data that demonstrated enhanced restriction of HIV when A3G and A3F are coexpressed 
126,144,237. Notably, the V5-tagged versions of A3F 231I and A3F 231V were able to decrease HIV 
infectivity more than the untagged proteins (Figure 3.1A and Figure 3.4A), but the difference in 
restriction between the two A3F variants was the same (Figure 3.1A, 50 ng, 1.6-fold, p≤0.01; 
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Figure 3.4A, 50 ng, 1.5-fold, p≤0.001). We also coexpressed A3F 231I-V5 and A3F 231V-HA 
(A3F 231I/A3F 231V) and found that the decrease in HIV infectivity was 2-fold (p≤0.05) and 1.5-
fold (p≤0.001) more than each A3F alone, respectively. These data suggest that the weaker 
restriction activity of A3F 231I does not negatively affect the stronger restriction activity of A3F 
231V. In addition, in the presence of Vif, coexpressed A3F 231V/A3F 231I was able to partially 
restrict HIV-1 (Figure 3.4A, p≤0.01). 
Immunoblotting of cell and virion lysates from the infectivity experiments demonstrated 
that the A3F 231V resulted in increased steady state levels and encapsidation of coexpressed 
proteins, A3F 231I or A3G. Since each coexpression condition had an HA- and V5- tagged A3, 
samples from the same cell lysate had to be detected on separate V5 (Figure 3.4B) or HA (Figure 
3.4C) blots. In both the presence and absence of Vif, increased HIV restriction correlated with 
increased steady state expression of A3F 231I-V5 when coexpressed with A3F 231V-HA (Figure 
3.4B). In the absence of Vif and the presence of A3F 231V-HA, the A3F 231I-V5 expression 
increased 8.4-fold (Figure 3.4B). In the presence of Vif and A3F 231V-HA, the A3F 231I-V5 
expression increased 2-fold (Figure 3.4B). A3G-HA expression levels in cells were increased in 
the presence of A3F 231V-V5 by 1.5-fold in the absence of Vif and 5-fold in the presence of Vif 
(Figure 3.4C). Effects on encapsidation were also observed in the presence of A3F 231V.  
Consistent with the partial restriction ability of A3F 231V/A3F 231I in the presence of Vif (Figure 
3.4A, 66% infectivity), there was encapsidation of coexpressed A3F 231I-V5 (Figure 3.4B, 
detectable encapsidation) and A3F 231V-HA (Figure 3.4C, 5-fold more in the presence of Vif) 
even in the presence of Vif. Although A3G-HA encapsidation in the presence (3-fold) and absence 
(5-fold) of Vif was increased when coexpressed with A3F 231V-V5, the HIV-1 infectivity in the 
presence of Vif was not decreased more than A3G-HA alone (Figure 3.4A and Figure 3.4C), 
consistent with previous results that Vif inhibits encapsidated A3G activity 193,194. Altogether, the 
data indicate that when A3F 231V is expressed, it can increase steady state levels and 
encapsidation of A3F 231I and A3G (Figure 3.4B and Figure 3.4C). Although there was no 
enhancement of A3G-HA encapsidation levels in the presence of A3F 231I-V5, A3G-HA was able 
to enhance A3F 231I-V5 cellular expression 10-fold in the absence of Vif and 8-fold in the 
presence of Vif (Figure 3.4B). The presence of A3G-HA resulted in higher A3F 231I-V5 virion 
encapsidation levels in the absence of Vif (10-fold), but no change in the presence of Vif (Figure 
3.4B, A3F 231I-V5 not detectable). Altogether, these data demonstrate that different A3s can 
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influence cellular expression levels and virion encapsidation, with A3F 231V having the highest 
effects. 
  
93 
 
  
Figure 3.3 A3F 231V and A3F 231I commonly occur as a heterozygous genotype and can 
interact in cells. The immunoprecipitation from cell lysates used either anti-V5 antibody or rabbit 
IgG (mock). Co-immunoprecipitation of A3F 231V-HA with A3F 231I-V5 or A3G-HA with A3F 
231V-V5 and A3F 231I-V5 was detected through the HA tag. The presence of the V5-tagged 
protein in the co-immunoprecipitation samples is also shown. The experimental and mock samples 
were from the same lysate. The lysate blot demonstrates the cellular expression of α-tubulin, HA, 
and V5. A nonspecific band in the V5 blot is marked with an asterisk. 
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Population1 Allele frequency (G/A)2 Genotype frequency 
ALL 0.50/0.50 G/G: 0.29 
A/A: 0.28 
A/G: 0.42 
AFR 0.81/0.19 G/G: 0.66 
A/A: 0.04 
A/G: 0.30 
EUR 0.51/0.49 G/G: 0.29 
A/A: 0.27 
A/G: 0.45 
AMR 0.38/0.62 G/G: 0.14 
A/A: 0.38 
A/G: 0.49 
EAS 0.29/0.71 G/G: 0.07 
A/A: 0.50 
A/G: 0.43 
SAS 0.39/0.61 G/G: 0.14 
A/A: 0.35 
A/G: 0.51 
Data were obtained from Ensembl genome browser (release 94) 267. 
1 Populations are abbreviated as All (ALL), African (AFR), European (EUR), Mixed American 
(AMR), East Asian (EAS), and South Asian (SAS). 
2 The A3F SNP rs2076101 is a G to A change that codes for A3F 231V (G) or A3F 231I (A). 
  
Table 3.2 Population analysis of alleles and genotype of A3F SNP rs2076101 that results in 
A3F 231V/I. 
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Figure 3.4 Co-expression of A3F 231V and A3F 231I results in enhanced HIV-1 restriction 
ability. (A) HIV-1 -Vif and +Vif infectivity was measured by β-galactosidase activity in reporter 
cells infected with HIV-1 that was produced in the absence or presence of A3G-HA, A3F 231V-
V5, A3F 231V-HA, or A3F 231I-V5 in the combinations shown in the graph legend. Error bars 
represent the standard deviations of the mean calculated from three independent experiments. (B) 
Immunoblotting with V5 antibody was used to detect cellular expression and virus encapsidation 
of A3F 231I-V5 in the presence of A3F 231V-HA or A3G-HA. (C) Immunoblotting with HA 
antibody was used to detect cellular expression and virus encapsidation of A3F 231V-HA or A3G-
HA in the presence of A3F 231I-V5 or A3F 231V-V5. (B-C) Samples in these panels are from the 
same cell lysates. One representative blot from three independent experiments is shown. The A3 
expression levels shown below blots were calculated by setting a –Vif condition for A3F 231I, 
A3F 231V, or A3G to 1.0 and determining the relative values of other lanes. A nonspecific band 
in the V5 and HA blots was observed and is marked with an asterisk. Immunoblots were conducted 
from three independent experiments and a representative blot is shown. 
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3.4.7 In the presence and absence of Vif, coexpressed A3F 231V and A3F 231I induce more 
mutations in HIV-1 proviral DNA 
To determine if the increased encapsidation of A3 enzymes resulted in increases in A3-
induced mutations, we PCR amplified and sequenced a 351 bp portion of HIV-1 protease. The 
data demonstrated that the tagged versions of A3F 231V, A3F 231I, and A3G induced similar 
numbers of mutations to their untagged versions (+Vif and –Vif, Table 3.1 and Table 3.3). When 
the tagged A3F 231V and A3F 231I are coexpressed and encapsidate into ΔVif HIV-1 virons, 
there is a 2-fold increase in mutations from A3F 231I alone and a 1.4-fold increase in mutations 
for A3F 231V alone (Table 3.3). Based on analysis of encapsidation, this is likely due to increased 
encapsidation of A3F 231V (Figure 3.5D). The conditions where A3G was coexpressed with an 
A3F, in HIV-1 ΔVif producer cells, did not have significant increases in the numbers of mutations 
above A3G alone, but when we examined the ratio of A3G induced mutations to A3F induced 
mutations based on the mutational footprint, we observed a 2.6 fold (A3F 231V) and 2-fold (A3F 
231I) increase in A3F-induced mutations in the presence of A3G (Table 3.3). Of more significance 
is that in the presence of Vif, there is a 2-fold increase in mutations from the A3F 231V alone 
condition (Table 3.3). Since A3F 231V and A3F 231I have the same deamination motif, we could 
not discern which variant is more active. However, based on analysis of encapsidation, since both 
had higher levels in virions (Figure 3.5C-D), the deaminations could be due to both A3F variants.  
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Table 3.3 Analysis of combined A3 expression on the induced mutagenesis in HIV-1 
proviral DNA. 
Virus 
Condition 
A3 enzyme Base 
pairs 
sequenced 
G→A 
mutations 
(total) 
GG→AG 
mutations 
(total) 
GA→AA 
mutations 
(total) 
G→A 
mutations 
(per kb) 
GG→AG 
mutations 
(per kb) 
GA→AA 
mutations 
(per kb) 
-Vif No A3 10881 0 0 0 0 0 0 
 A3F 231V-
V5 
10530 27 1 26 2.56 0.09 2.47 
 A3F 231I-V5 8073 15 1 14 1.86 0.12 1.73 
 A3F 231V-
HA/A3F231I-
V5 
12285 45 1 44 3.66 0.08 3.58 
 A3G 6669 121 109 11 18.1 16.3 1.64 
 A3G-
HA/A3F 
231V-V5 
10530 172 102 70 16.3 9.69 6.64 
 A3G-HA/ 
A3F 231I-V5 
12987 134 95 39 10.3 7.32 3.00 
+Vif No A3 11934 0 0 0 0 0 0 
 A3F 231V-
V5 
10530 6 1 5 0.57 0.09 0.47 
 A3F 231I-V5 10881 1 0 1 0.09 0 0.09 
 A3F 231V-
HA/A3F231I-
V5 
11232 11 0 11 0.98 0 0.98 
A 351 bp region of HIV-1 protease was PCR amplified from the three independent single-cycle 
replication experiments shown in Figure 3.4. Clones were sequenced, aligned with Clustal 
Omega 268, and analyzed using Hypermut 269.  
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3.5 Discussion 
In HIV-1 genomes isolated from HIV+ individuals, there are mutational footprints in the (+) DNA 
at both 5′GG→5′AG and 5′GA→5′AA motifs 127,156,195-204,258. The 5′GG→5′AG are clearly 
attributable to A3G 125. The origins of the 5′GA→5′AA mutations have been attributed to stable 
A3H haplotype (II, V, VII) induced mutations, due to an inability of some HIV-1 Vif variants to 
efficiently induce degradation of A3H 127,264. The role of A3D in inducing these mutations is 
known to be minor, but still significant 131,136,218,236,270. However, the role of A3F has been 
significant in some reports, but not others 126,131,133,217,218,233,234. In individual experiments with 
A3F, the mutational load is lower than A3G and A3H and this seemed incongruent with data 
demonstrating that A3F exerts a direct selective force on HIV-1 Vif and provides a protective 
effect in pretreatment HIV-1 cohorts 77,133,135,160,217,271. Here we provide a possible explanation for 
these data demonstrating that the A3F 231V in comparison to the A3F 231I is more stable in cells, 
is partially protected from Vif-mediated degradation, is more highly encapsidated into virions, 
induces more mutations, and can increase encapsidation of coexpressed A3F 231I and A3G. These 
data suggest that the A3F 231V through its own action and hetero-oligomerization with A3F 231I 
or A3G is a contributor to G→A mutations in HIV+ individuals.  
 A protective effect of A3F 231V was demonstrated through genetic association analysis of 
pretreatment cohorts 160. Through this analysis it was shown that even when data were adjusted for 
known genetic factors (HLA allele and CCR5) the presence of even one A3F 231V allele could 
significantly delay progression to clinical AIDS and lower viral load 160. The authors suggested 
that this was due to partial resistance of A3F 231V to Vif, which had also been reported previously 
126,160. Here we show that the A3F 231V is protected from Vif mediated degradation in cells more 
than A3F 231I and this results in more A3F 231V encapsidation (Figure 3.1). However, the A3F 
231V was not “resistant” to Vif mediated degradation, consistent with the 231 amino acid not 
being within the Vif binding interface 186,190,265,266. The protection from Vif appears to be due to 
the higher steady state level of A3F 231V in cells due to enhanced stability (Figure 3.1 and Figure 
3.2). Due to the high frequency of heterozygosity of the A3F 231V and A3F 231I and the lack of 
sensitive native A3F antibodies, we were unable to demonstrate the higher expression of A3F 
231V in primary cells (Table 3.2 and data not shown). However, when equal amounts of A3F 
231V and A3F 231I were expressed in cells, the capacity of Vif to induce degradation of both 
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enzymes was similar (Figure 3.2B-C). Rather, the data suggest that the higher steady state levels 
of A3F in cells exceeds the degradation capacity of Vif. Despite the protective effect of A3F 231V 
in HIV+ individuals 160, the partial protection of A3F 231V from Vif mediated degradation resulted 
in at most a 20% decrease in infectivity in a Vif+ HIV-1 single-cycle replication experiment 
(Figure 3.1B). More consistent with the An et al. study was 4-fold more G→A mutations induced 
by A3F 231V than A3F 231I in the presence of Vif (Table 3.1) 160. These small effects in our cell-
based studies are similar to data available for the A3G H186R polymorphism. The A3G H186R 
polymorphism results in only a 2-fold decrease in A3G processivity and mutations induced in an 
in vitro assay 134, but is nonetheless linked with faster progression to AIDS in HIV+ individuals 
210,211. Altogether, the data suggest that these small differences identified in cell culture can have 
an effect in HIV+ individuals. A possible explanation for this is that the small effects observed in 
cell-based studies become cumulative in multiple HIV replication cycles. In addition or 
alternatively, the coexpression and hetero-oligomerization of A3 enzymes may amplify this effect. 
The coexpression of A3F 231V and A3F 231I increased the encapsidation of both A3F variants in 
the presence of Vif and resulted in a corresponding 1.7-fold increase in mutations and infectivity 
of 66% (Figure 3.4B, Figure 3.4C, and Table 3.3). Our data and previous analysis demonstrate that 
there are synergies between A3 enzymes that can enhance anti-HIV activity, either directly due to 
changes in the biochemical characteristics of the enzymes or due to enhanced encapsidation in the 
presence of Vif (Figure 3.4) 144. Despite observations that A3F 231V on its own is partially 
protected from Vif-mediated degradation and our observation that A3F 231V appears to protect 
A3G from Vif-mediated degradation, the mechanism is not known 126,160. 
 Further, the reason for the stability differences between A3F 231V and A3F 231I remain 
to be elucidated. Consistent with our observations, a nucleotide variant prediction model suggested 
that the A3F linked SNPs can have an effect on stability (Figure 3.1 and Figure 3.2) 160. The amino 
acid 108 is on predicted helix 3 in the noncatalytic N-terminal domain (NTD) and the amino acid 
231 is on β-strand 2 in the catalytic C-terminal domain 92,186,272,273. Neither of these structures are 
near the catalytic center, predicted nucleic acid binding motifs, or the Vif interface 92,186,190,272,273. 
Although V231I is a conservative amino acid change, a Val to Ile amino acid change in other 
proteins, e.g., transthyretin, has been found to destabilize equilibrium kinetics of oligomerization 
and result in physiological dysfunction 274. The A108S is a nonpolar to polar amino acid change 
and the Ser can form hydrogen bonds, unlike Ala, which may alter protein stability 275.  
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3.4.6 Conclusions  
 In aim 2 we observed that the virus that was exposed to multiple rounds of deamination 
had less RT activity and subsequently less viability compared to the no A3 or singly exposed to 
A3s conditions. Moreover, our experiments showed that there were also variations within the virus 
populations that were exposed to multiple rounds of deaminations. Since the type of the A3 enzyme 
that was used in the experiments were similar, we hypothesized that this variation could be due to 
polymorphism in A3 family. Genotyping of the CEM and PBMCs that endogenously express A3s 
showed that our donor’s PBMCs harbored the less restrictive variant of A3F with Isoleucine in 
position 231 and CEM cells were heterozygous for A3F (A3F231I/A3F231V). Considering the 
results of other studies showing that harboring A3F 231V allele was associated with delayed 
progression to AIDS 160 and the results of aim 2 that A3s cooperate to insure maximum restriction 
of HIV-1 we sought to investigate the impact of A3F polymorphism on HIV-1 infectivity in aim3. 
Our data demonstrated that the A3F 231V has higher steady state expression levels in cells and 
virion encapsidation than A3F 231I, in the presence and absence of Vif. This results in larger 
decreases in HIV-1 infectivity and higher mutation rates. The disruption of Vif-mediated 
degradation through hetero-oligomerization of A3s may be an example of increasing host 
restriction factor diversity to combat virus evolution 164,276. Altogether, this supports a model in 
which not only the genetic diversity of the host for each A3, but the ability of these A3s to 
functionally interact can contribute to a diverse and multifaceted protective response during HIV-
1 infection. 
3.6 Materials and Methods 
3.6.1 Plasmids and Transfection Conditions 
To express two A3 enzymes on a single-cell level, the pVIVO2 plasmid (Invivogen) that contains 
two transcriptional units was used. For comparison to double expression experiments, pVIVO2 
was also used to express single A3 enzymes. The cloning of A3G-HA, A3F 108S/231I-V5, and 
A3G-HA/A3F 108S/231I-V5 into pVIVO2 was previously described144. The pcDNA A3F 
108A/231V was kindly provided by Reuben Harris (University of Minnesota) and subcloned into 
pVIVO2 using the same cloning strategy as previously reported to create A3F 108A/231V-V5, 
A3F 108A/231V-HA, and A3G-HA/A3F 108A/231V-V5, and A3F 108A/231V-HA/A3F 
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108S/231I-V5144. Primer sequences are available on request. Untagged constructs of A3G, A3F 
108S/231I, and A3F 108A/231V were expressed from pcDNA and were previously reported126,133. 
Since the A3F polymorphisms at 108 and 231 are in strong linkage disequilibrium, for brevity we 
refered to the A3F forms as either 231I or 231V160,212,233. 
3.6.2 Single-cycle infectivity assays 
VSV-G pseudotyped HIV-1 LAI ΔVif ΔEnv were produced by transfecting 1 x 105 293T cells per 
well of a 12-well plate. The 293T cells were maintained in DMEM with 10% FBS. GeneJuice 
(Novagen) transfection reagent was used as per manufacturer’s protocol. Cells were transfected 
with 500 ng of pHIV-1 LAI ΔVif ΔEnv, 180 ng of pMDG, which expresses VSV-G, and 25, 50, 
or 100 ng of A3 expression plasmid260,277. The following pVIVO2 constructs were transfected for 
expression of tagged A3s: A3G-HA, A3F 231V-V5, A3F 231I-V5, A3G-HA/A3F 231I-V5, A3G-
HA/A3F 231V-V5, and A3F 231V-HA/A3F 231I-V5. The following pcDNA3 constructs were 
transfected for expression of untagged A3s: A3G, A3F 231V, and A3F 231I. To equalize the 
amount of plasmid DNA transfected, empty pVIVO2 or pcDNA3 vectors were used. After 24 h 
the media was changed and virus containing supernatants were harvested 24 h after the media 
change. Supernatants were filtered through a 0.45 μm polyvinylidene difluoride (PVDF) syringe 
filter.  
For infection of a reporter cell line to determine infectivity 1 x 104 cells per well of a 96-well plate 
containing either HeLa CD4+ HIV-1 LTR-β-gal (MAGI) or TZM-Bl cells were infected with a 
serial dilution of virus in the presence of 8 μg/mL polybrene. Forty-eight hours after infection the 
cells were washed with PBS and infectivity was measured through colorimetric detection using a 
β-galactosidase assay reagent (Pierce) and spectrophotometer. Infectivity of each virus was 
compared by using the infectivity of the No A3 condition as 100%. 
3.6.3 Quantitative immunoblotting 
293T cells expressing No A3, A3G-HA, A3F 231V-V5, A3F 231I-V5, A3F-231V-HA, A3G-
HA/A3F 231I-V5, A3G-HA/A3F 231V-V5, and A3F 231V-HA/A3F 231I-V5 from the single-
cycle infectivity assays were detected using rabbit anti-HA (1:1000, Sigma) or rabbit anti-V5 
(1:500, Sigma). 293T cells expressing No A3 or untagged A3G, A3F 231V, or A3F 231I were 
detected with ApoC17 rabbit antiserum (1:1000; Cat# 10082, NIH AIDS Reagent Program) for 
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A3G or rabbit anti-APOBEC3F antibody, C-term (1:500; Cat# GTX47211, Genetex) for 
A3F278,279. A3s were detected in cell lysates and virions. Cells were lysed using 2x Laemmli Buffer 
and 40 μg total protein was used. Virus was concentrated using Retro-X (Clontech) following the 
manufacturer’s protocol and 20 μL of concentrated virus was used. Loading controls for cell 
lysates (α-tubulin, Sigma) and virus (p24, Cat #3537, NIH AIDS Reagent Program) were detected 
with mouse monoclonal antibodies. Secondary detection was performed using Licor IRDye 
antibodies produced in goat (IRDye 680-labeled anti-rabbit and IRDye 800-labeled anti mouse).  
To detect Vif-mediated degradation of A3s, 1 x 105 293T cells per well of a 24-well plate were 
transfected with 50 ng of A3F 231I-V5, 10 ng A3F 231V-V5, or empty pVIVO2 (No A3) and a 
titration of VifLAI expression plasmid (0,10, 25, 50, 100, and 200 ng). A 5-fold greater amount of 
A3F 231I was required to equalize the expression of both A3Fs. GeneJuice (Novagen) transfection 
reagent was used as described by the manufacturer. The media (DMEM and 10% FBS) was 
changed 24 h after the transfection. The cells were harvested 24 h after the media change with 2x 
Laemmli buffer and 40 μg total protein was used. Vif was detected with HIV-1 Vif monoclonal 
antibody (1:1000; Cat# 6459, NIH AIDS Reagent Program), followed by incubation with 
secondary goat anti-mouse IRDye 680RD. The V5-tagged A3F and α-tubulin was detected as 
described. 
3.6.4 Co-immunoprecipitation assay 
The co-immunoprecipitation method was previously described144,262. In brief, 2.5 x 106 293T cells 
per 75 cm2 flask were transfected with 1 μg total DNA using GeneJuice (Novagen) as per 
manufacturer instructions. The plasmids transfected expressed A3G-HA/A3F 231I-V5, A3G-
HA/A3F 231V-V5 or A3F 231V-HA/A3F-231I-V5. Each cell lysate was split into two fractions 
that were either used in a co-immunoprecipitation with nonspecific mouse IgG (mock) or the 
mouse anti-V5 (experiment). The co-immunoprecipitations were conducted in the presence of 
RNase A144. A mouse anti-V5 (1:1000, Sigma) was used for immunoprecipitations and proteins 
were detected on the membrane using the same V5 antibody, mouse anti-HA (1:1000, Sigma), and 
polyclonal rabbit anti-α-tubulin (1:1000; Sigma). Secondary antibodies used were Licor IRDye 
antibodies IRDye 800-labeled goat anti-mouse and 680-labeled goat anti-rabbit secondary 
antibody. 
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3.6.5 Sequencing of integrated proviral DNA 
For proviral sequencing, 1 x 105 293T cells per well of a 24-well plate were infected with 
supernatant containing virus in the presence of 8 μg/mL polybrene. The plates were spinoculated 
at 800 x g for 1 h. Cell were harvested after 48 h by removing the media, washing with PBS, and 
lysing the cells and extracting DNA with DNAzol (Invitrogen). The PCR amplification of the 
protease region of HIV-1 (351 bp) and treatment of DNA with DpnI was carried out as previously 
described133. Sequences were analyzed with Clustal Omega268 and Hypermut269. 
3.6.6 Genotyping Donor Peripheral Blood Mononuclear Cells 
PBMCs were isolated from whole blood samples using Ficoll-Paque (GE-Healthcare) density 
gradient centrifugation in Sepmate50 tubes (STEMCELL Technologies). DNA was isolated from 
donor PBMCs using a PAXgene Blood DNA Kit (Qiagen). The A3G and A3F polymorphic sites 
were amplified using PCR. The A3G H186R polymorphism was detected using the following 
primers: (forward) 5′ AATTTCAGCACTGTTGGAGC and (reverse) 5′ 
GAGAATCTCCCCCAGCAT. The A3F V231I polymorphism was detected using the following 
primers: (forward) 5′ AGCCTATGGTCGGAACGAAA and (reverse) 5′ 
CTGGTTTCGGAAGACGCC. The PCR amplification used Q5 High Fidelity polymerase (New 
England Biolabs) and cycling conditions were 95° C for 5 min followed by 45 cycles of 95° C for 
10 sec, 52° C for 20 sec, 72 ° C for 20 sec. Amplicons were cloned into pJET1.2 using the 
CloneJET PCR cloning kit (ThermoScientific). Amplicons were Sanger sequenced at the National 
Research Council of Canada (Saskatoon, Saskatchewan). The resulting A3G and A3F sequences 
were translated using the Expasy Translate tool to identify polymorphisms 280. Six clones from 
each donor were analyzed for A3G H186R and A3F I231V polymorphisms to determine 
homozygosity or heterozygosity of each allele in combination with allelic frequency.  
3.7 Ethics Statement 
This study has been reviewed and approved by the Research and Ethics Board at the University of 
Saskatchewan (Bio# 14-62 and 13-293). Peripheral Blood Mononuclear Cells (PBMCs) were 
isolated from de-identified individuals of European ancestry. In accordance with OCAP® 
principles and in consultation with several Indigenous stakeholders, no samples of Indigenous 
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Peoples were included. Donors were either HIV+ and recruited through the Positive Living 
Program (PLP) at the Royal University Hospital, Saskatoon or HIV- Donors (HD). 
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4.0. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
HIV-1 is a major health problem that has taken over 35 million lives. HIV/AIDS results in 
deficiency of immune system by attacking CD4+T cells causing rare cancers and opportunistic 
infections for an infected individual. Constant genetic diversity in the replicating population of the 
virus is a challenging obstacle facing developing a successful HIV vaccine. Understanding all the 
contributors to this genetic diversity helps scientists to tackle this barrier and design successful 
antiretroviral drugs. A3 enzymes despite their intrinsic antiretroviral activity are one of the 
potential contributors to this genetic variation. However, there have been controversial reports on 
this contribution and the extent to which A3-mediated mutagenesis can take part in the 
development of drug resistance is not clear. Despite A3G being discovered 17 years ago, we are 
still discovering new functions of these enzymes. In this work we incorporated recent findings 
about A3 enzymes to come to a broader conclusion regarding the contribution of A3 enzymes to 
virus evolution. 
In 2017 a study from our lab by Ara et al. demonstrated that A3F and A3G form a 
tetrameric hetero-oligomer when expressed together. Using purified proteins and size exclusion 
chromatography, the study showed that the hetero-oligomer contained a trimeric A3F and a 
monomer A3G. The co-IP results further showed that this hetero-oligomerization is through an 
RNA independent protein-protein interaction in the cells144. This hetero-oligomerization resulted 
in cooperative restriction of ΔVif HIV-1. This enhanced antiretroviral activity in the absence of 
Vif was due to improved mutagenesis of the A3s and the ability of the tetramer to slow down the 
reverse transcriptase by acting as a road block144. However, the extent to which these proteins 
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oligomerize in the presence of a WT HIV and their impact on the replication of WT HIV was 
unknown. Here, we showed that in the presence of Vif, A3F indeed hetero-oligomerizes with both 
A3G and A3F. This hetero-oligomerization equips the A3F with a partial protection to the action 
of Vif. This resistance recovers the mutagenic activity of A3F in the presence of Vif which would 
have less than the error rate of RT if A3F was expressed alone. However, the reason behind this 
partial protection is not fully understood.  
Similar results were found with coexpressioin of A3F 231I/231V. The enhanced HIV 
restriction activity of the hetero-oligomer of A3F231I/231V appears to be due to the better 
expression level of A3F231V that results first, in the presence of increased numbers of available 
A3F molecules in the cytoplasm which can exceed its degradative capacity and second, to increase 
that stability of the hetero-oligomerized partner (A3F 231I). For the A3F/G, the protection from 
Vif could be due to the conformational changes that oligomerization offers which can block the 
Vif binding site on the A3s. However, Vif is known to disrupt A3G oligomerization which can 
affect the processivity of the enzyme262. The improved protection of only A3F in this tetrameric 
hetero-oligomer suggests that Vif is unable to break up A3G hetero-oligomerization with A3F. 
This work demonstrates that A3F is more important for HIV restriction than previously 
thought, either alone or in combination with A3G in restriction of HIV. As a result, this work 
suggests that more polymorphisms should be taken into account when the effect of A3s in 
retroviral suppression and evolution is being studied since the properties of A3s are different when 
hetero-oligomerized or alone. This raises the question about the accountability of the results of the 
studies overlooking the effect of the A3s when hetero-oligomerized. The CEM cells with 
endogenous expression of A3s are extensively used in HIV field and have heterozygous A3F 
alleles. This heterozygosity provides different properties for the cells than the homozygosity by 
A3F 231I; this could explain different conclusions of A3F involvement in HIV restriction from 
experiments from different labs that did or did not use CEM cells. Besides CEM cells, other A3 
producing cells like H9 and SupT1are widely used and have not been genotyped. 
In this study we focused on A3F and A3G since these proteins are the most restrictive of 
the five members and are commonly expressed together in the human population230,231. However, 
based on the fact that A3s get encapsidated in a non-competitive way through binding 
nonspecifically to cellular RNAs that HIV Gag is also bound to, the potential hetero-
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oligomerization of different A3 pairs should be considered as this may affect activity. For example, 
A3D is the least active enzyme137, but is most closely related to A3F, suggesting that they may be 
able to hetero-oligomerize. The effect of this on HIV restriction activity should be investigated to 
determine if hetero-oliomerization always promotes HIV restriction, or if some A3 pairs result in 
less A3 restriction. Further, in our experiments we used lab isolates of virus had a limited duration 
of infection (30 days), but in the future it would be interesting to use clinical isolates of viruses 
from early and chronic infections and continually passage the virus to determine how quickly the 
A3-mediated mutations accumulate in proviral genomes.  
Overall, this study showed that A3 proteins cooperate to enhance the viral suppression. The 
data support a model that this cooperation is a counteraction against Vif-mediated degradation to 
increase the efficiency of the HIV-1 restriction. Perhaps this mechanism and affinity of A3s to 
hetero-oligomerize could be used develop more efficient antiviral drugs.  
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